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Helicobacter pylori (H. pylori) infection is a major cause of chronic gastritis and 
peptic ulcer disease, and it is also designated as a class-I carcinogen for stomach 
cancer. The role of probiotics in the treatment of gastrointestinal infections is 
increasingly documented as an alternative or complement to antibiotics, with the 
potential to decrease the use of antibiotics or reduce their adverse effects. 
These studies were conducted to investigate the role of probiotics in the treatment 
of H. pylori infection. Various aspects included: an investigation of the effects of 
a probiotic combination consisting of Lactobacillus rhamnosus GG, L. rhamnosus 
LC705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve 
Bb99 or B. lactis Bb12 as a supplementation to H. pylori eradication therapy, with 
special reference to tolerability, effectiveness, and microbiota alterations following 
the treatment; discovering the role of probiotics in vivo with H. pylori infected and 
uninfected patients, as well as with an in vitro model of H. pylori infection.
The probiotic combination therapy was able to reduce significantly the total 
symptom score, which takes into account both the frequency and the severity of 
the adverse effects, during the eradication treatment. The supplementation did 
not improve the success of the eradication treatment significantly, though some 
difference was seen in the eradication percentages (91% vs. 79%). The quantities 
of predominant bacterial groups were altered significantly following the triple 
treatment. Probiotics slightly counteracted the effects of anti-H. pylori treatment, 
monitored as significantly less alterations in the total numbers of aerobes and 
lactobacilli / enterococci group bacteria. 
After probiotic intervention, L. rhamnosus GG adhered to a minority of the 
patients’ upper gastrointestinal mucosa, but all of the probiotics survived well 
through the gastrointestinal tract transit with and without antimicrobial treatment. 
Probiotic intervention decreased gastrin-17 levels in H. pylori infected patients and 
appeared to decrease the 13C-urea breath test values. In in vitro Caco-2 cell line 
experiments, probiotics inhibited H. pylori adhesion to intestinal epithelial cells. 
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Both L. rhamnosus strains, P. freudenreichii ssp. shermanii JS and the combination 
inhibited the H. pylori-induced acute cell leakage. Simultaneously, both L. 
rhamnosus strains and the combination transiently improved the epithelial barrier 
function. The pro-inflammatory effects prevailed when the probiotics were used 
in combination. 
According to this series of studies, probiotic combination could have some 
potential in reducing adverse effects induced by H. pylori eradication treatment 
and beneficial effects on H. pylori infected subjects.
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inTroducTion
Helicobacter pylori (H. pylori) infection is recognized as a causative agent for 
acute and chronic gastritis and as a predisposing factor to peptic ulcer disease, 
gastric cancer and gastric lymphoma. This important discovery, rewarded with 
the 2005 Nobel Prize in Medicine, has changed gastroenterological practice 
worldwide since, after its discovery, many gastroduodenal diseases became curable 
infectious diseases. The prevalence of H. pylori infection in the adult population of 
industrialized countries is estimated to be at 20–50%, and in developing countries, 
the rate is as high as 80% (for review, see Go 2002). The rate of carriage increases 
according to age group. Infection is usually acquired during childhood and persists 
lifelong if not treated specifically.
Only a combination of antimicrobials can be used in vivo to eradicate 
H. pylori, and none of the antimicrobials is effective enough to eliminate H. pylori 
when given as monotherapy (for review, see Kusters et al. 2006). The first-line 
recommended eradication treatment of H. pylori consists of a combination of two 
antimicrobials and an acid-suppressive drug (Malfertheiner et al. 2002). However, 
the triple treatment has many shortcomings, such as several adverse effects possibly 
leading to discontinuation of the treatment (Deltenre et al. 1998), and limited 
efficacy particularly because of antimicrobial resistance (for review, see Gerrits et 
al. 2006). 
In recent years, the development of alternative anti-H. pylori treatments has been 
actively pursued, and investigations have been carried out to define components 
that could be used either as monotherapy or synergistically in combination with 
antimicrobials thus resulting in more effective anti-H. pylori therapy or alternative 
ways of controlling H. pylori infection. These novel treatments could potentially 
reduce the costs related to the treatment of H. pylori associated diseases. Promising 
results have been obtained in initial studies with several probiotic strains (for reviews, 
see Hamilton-Miller 2003, Gotteland et al. 2006), but there are still many open 
questions. As defined by FAO/WHO (2002), probiotics are live microorganisms 
that, when administered in adequate amounts, confer a health benefit on the host 
(such as Lactobacillus spp. and Bifidobacterium spp.). 
The present study aims to investigate the effects of probiotics in patients 
receiving the recommended eradication treatment for H. pylori infection, as well as 
the effects on the stomach and intestine in untreated H. pylori-positive patients, and 
to evaluate the characteristics of individual probiotics or the probiotic combination 
in an in vitro model of H. pylori infection.
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1. gasTroinTEsTinal  
dEfEncEs againsT paThogEns
Natural gastrointestinal defences against pathogens can be theoretically divided 
into three levels of responses (for reviews, see McCracken and Lorenz 2001, 
Bourlioux et al. 2003). The host's microbiota provides the first level of defence 
against pathogens by preventing them from developing in the gastrointestinal 
tract, for instance, by protecting the mucosa against colonization of pathogenic 
microorganisms. The intestinal epithelium constitutes a second level of defence 
and a tight barrier against pathogens by the combined effect of the mucus layer and 
the epithelial cells themselves. The immune system, which constitutes the third 
defensive barrier against pathogenic microorganisms, can be divided into two lines 
of defence against pathogens: innate and adaptive immunity. 
1.1 guT MicrobioTa
Composition and diversity of gut microbiota
The human microbiota is considered to be an enormously diverse and complex 
ecosystem affected by host cells, ingested food and microbes (for review, see 
Zoetendal et al. 2006). In the past, it was commonly believed that over 400 species 
compose this microbiota. However, it is nowadays estimated that more than 1,000 
rEviEw of  
ThE liTEraTurE
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species are present in the gut (Bäckhed et al. 2005). Previously, traditional methods 
using culturing have been used as the gold standard for investigating bacteria. 
However, use of 16S ribosomal RNA (rRNA) and genome based approaches has 
revealed further information about microbiota. The new culture-independent 
techniques, such as sequencing of cloned 16S rRNA gene amplicons, 16S rRNA 
gene fingerprinting, quantitative fluorescent in situ hybridization (FISH), and 
quantitative polymerase chain reaction (PCR), provide more specific methods for 
detailed investigations at the species and strain levels (Zoetendal et al. 2006). Also, 
development of high-diversity deoxyribonucleic acid (DNA) microarrays will open 
new possibilities in gut microbiota research (Rajilic-Stojanovic et al. 2006). Thus, 
new microbes in the human microbiota are continuously being discovered. It has 
been suggested that only 20–40% of the bacteria from intestinal samples have 
been characterized, due to a lack of knowledge of appropriate culture conditions 
(Zoetendal et al. 1998, Suau et al. 1999, Hayashi et al. 2002). 
There are very few studies on the microbiota of the stomach with culture-
independent techniques, and recent evidence indicates that the stomach microbiota 
is also more diverse than previously thought (Hill 1985, Monstein et al. 2000, Peña 
et al. 2002, Roos et al. 2005, Bik et al. 2006). The most common bacterial phyla 
found in the stomach are Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria and 
Fusobacteria, and the most abundant genera found are Helicobacter, Streptococcus 
and Prevotella (Bik et al. 2006). Thus, even in young normochlorhydric subjects, 
the lumen is not bacteria free, despite pH values being most of the time below 3. 
However, the gastric acid is buffered during a meal, allowing microbes to proliferate. 
Impaired gastric acid secretion, caused, for example, by chronic atrophic gastritis, 
prolonged use of histamine-2 receptor antagonists or proton pump inhibitors, is 
associated with bacterial overgrowth in the stomach and small intestine (Hill 1985, 
Väkeväinen et al. 2000, Sanduleanu et al. 2001, Williams and McColl 2006).
The composition of the predominant bacterial community in the gut is reported 
to be host-specific and stable over time in healthy adults (for review, see Zoetendal 
et al. 2006). Only a limited fraction of bacterial phyla compose the major intestinal 
microbiota (Manichanh et al. 2006). In healthy adults, 80% of phylotypes belong 
to four major phylogenetic groups, which are the Clostiridium leptum, Clostridium 
coccoides, Bacteroides and Bifidobacteria groups (Lay et al. 2005). However, a large 
fraction of dominant phylotypes is subject specific (Zoetendal et al. 1998, Seksik 
et al. 2003, Vanhoute et al. 2006). Also, recent studies have found that mucosal 
microbiota is stable along the distal gastrointestinal tract from ileum to rectum, 
but mucosa-associated microbiota is different from fecal microbiota. The difference 
has been estimated to be between 50–90% (Zoetendal et al. 2002, Lepage et al. 
2005). 
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The importance of microbes for the host
The intestinal microbiota has crucial physiological functions in the gut, such 
as metabolic capacity and the ability to ferment carbohydrates into short-chain 
fatty acids, which have been shown to stimulate the growth and well-being of 
the colonic mucosa and colonic motility (for reviews, see Mitsuoka 2000, O’Hara 
and Shanahan 2006). Studies of germ-free mice have revealed that gut microbiota 
plays an important role in the maturation of the immune system (for review, see 
Hooper et al. 2002). The intestine of germ-free mice has several physiological 
differences as compared to that of conventional mice and also a less developed 
immune system. Several other specific interactions between host and bacteria have 
also been discovered using germ-free animal models and in vitro cell models. These 
include antimicrobial peptide production, maintenance of intestinal homeostasis 
and development of vascular network in the villi after microbial colonization 
(Zoetendal et al. 2006). Thus host-microbe interactions can shape the immunity 
and maturation of the gastrointestinal tract of the host and have a further impact 
on the ecology of microbiota. The balance between potentially beneficial and 
harmful bacteria is very important (Figure 1).
Figure 1 Potentially harmful and potentially beneficial bacteria (Modified from Bourlioux et al. 2003). P., 
Pseudomonas; G+, Gram positive; E., Escherichia.
Colonization resistance
The indigenous microbiota is a natural resistance factor against potential pathogenic 
microorganisms and provides colonization resistance, also known as gut barrier, by 































and Clasener 1994). It has been suggested that commensal bacteria protect their 
host against microbial pathogens by interfering with their adhesion and toxic 
effects (for reviews, see Brook 1999, Servin et al. 2004).
1.2 gasTroinTEsTinal EpiThEliuM
The tight epithelial cell barrier forms the second line of defence between the gut 
luminal contents and the host. Epithelial cells lining the gastrointestinal tract are 
able to respond to infection by initiating either nonspecific or specific host-defence 
response (for reviews, see Kagnoff and Eckmann 1997, Strober 1998). Bacterial 
adhesion to the host cell or recognition by the host cell is often an essential first 
stage in the disease process. 
A wide range of gastrointestinal cell surface constituents, such as several 
glygoconjucates, can serve as receptors for bacterial adherence (Servin and Coconnier 
2003, Pretzer et al. 2005). Furthermore, epithelial cells express constitutively host 
pattern recognition receptors, such as Toll-like receptors (TLR). These are a family 
of transmembrane receptors that recognize repetitive patterns, i.e. the pathogen-
associated molecular patterns present in diverse microbes, including gram-positive 
and gram-negative bacteria (for reviews, see Bäckhed and Hornef 2003, Takeda 
et al. 2003). TLRs are also found on innate immune cells, such as dendritic cells 
and macrophages (Vinderola et al. 2005). TLR4 recognizes lipopolysaccharide and 
gram-negative bacteria, while TLR2 recognizes a variety of microbial components, 
such as peptidoglycan and lipoteichoic acids, from gram-positive bacteria (Abreu 
2003, Matsuguchi et al. 2003, Takeda et al. 2003). Also, several other TLRs with 
specific actions are known, such as TLR5, which responds to the bacterial flagella 
(Rhee et al. 2005), and TLR9, which is activated by bacterially derived short 
DNA fragments containing CpG sequences (Pedersen et al. 2005). Other known 
recognition receptors are nucleotide-binding oligomerization domain proteins, 
which recognize both gram-positive and gram-negative bacteria. They are located 
in cell cytoplasm and are implicated in the induction of defensins. 
Increased epithelial barrier permeability is frequently associated with 
gastrointestinal disorders contributing to both disease onset and persistence (for 
reviews, see Lu and Walker 2001, Berkes 2003). The gatekeeper of the paracellular 
pathway is the tight junction, which is an apically located cell-cell junction 
between epithelial cells. The tight junction permits the passage of small molecules, 
such as ions, while restricting the movement of large molecules, such as antigens 
and microorganisms, which can cause inflammation. The integral membrane 
protein family, which are mainly claudins, occluding and zonula occludens 1, 
are implicated in the formation of the paracellular channels (Berkes et al. 2003). 
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The permeability of the tight junction to ions can be assessed by transepithelial 
electrical measurements and by paracellular ion flux assays for major extracellular 
ions, such as Na+, Cl–, Ca2+, and Mg2+.  
Epithelial cells are also involved in a wide range of mucosal immune and 
inflammatory responses together with dendritic cells, macrophages, neutrophils and 
lymphocytes. Epithelial cells can secrete pro- and anti-inflammatory cytokines and 
chemokines, such as tumor necrosis factor (TNF) -α, interleukin (IL) -2, IL-6, and 
IL-8, which either diminish or stimulate response or provide feedback (Goodrich 
and McGee 1998). IL-8, a C-X-C chemokine that is transcriptionally regulated by 
nuclear factor-kappa B, shows potent chemotactic activity for neutrophils. Intestinal 
epithelial cells also secrete many other mediators involved in immune responses to 
potentially pathogenic microorganisms, including antimicrobial peptides, such as 
defensins and mucins (for review, see Servin 2004). The immunoinflammatory 
reaction is highly important in eliminating pathogens, but this reaction must be 
controlled to avoid the risk of a more widespread inflammation. Microbes differ in 
terms of their ability to induce inflammatory response. The commensal microbiota 
produces a very mild inflammation response and is thus tolerated by the mucosa, 
while modified microbiota induces a more marked response (for review, see O’Hara 
and Shanahan 2006). 
1.3 guT iMMunE sysTEM
The third level of defence is the immune system, which is crucial for humans 
and animals in protecting the host against invading pathogens. Bacteria are the 
main source of antigenic materials, and the gut microbiota is the most important 
stimulant of the body’s immunological defence (Bourlioux et al. 2003). The 
immune system comprises a complex array of interacting mechanisms. It consists of 
local immune tissue (mucosa associated lymphoid tissue) and the systemic immune 
system (in blood, liver, spleen and bone marrow). Both components can be further 
theoretically divided into two types of response: innate (nonspecific) and adaptive 
(specific) immune response (for reviews, see Borregaard et al. 2000, Janeway and 
Medzhitov 2002). Specific immune response is usually induced by direct contact, 
despite an intact epithelial barrier, between the lymphoid tissue and the potentially 
pathogenic macromolecules or microorganisms in the intestinal lumen. 
Innate or “natural” immunity is a rapidly activated host defence that recognizes 
conserved microbial structures not expressed by the host and mounts a nonspecific 
immune response against these structures (often specific carbohydrates or 
lipoproteins). The activated effectors of innate immunity, such as phagocytic cells, 
natural killer cells, and the complement system, are able to destroy the invader 
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(Suffredini et al. 1999, Borregaard et al. 2000, Janeway and Medzhitov 2002). 
Innate immunity also includes acid in the stomach, lysozyme, lactoferrin and 
antimicrobial molecules (Borregaard et al. 2000). Intracellular pathogens, like 
viruses, are killed by natural killer cells. 
The adaptive immune system is activated by the infection if the innate 
immune system is insufficient (Borregaard et al. 2000). The adaptive immune 
system is a more specific and powerful tool against pathogens, but the primary 
response mounts slower than in innate immunity. Crucially, adaptive immunity 
develops a memory, which enables a rapid and effective response in a reinfection. 
Adaptive immunity recognizes antigenic structures (often peptides), not expressed 
in the host, as non-self. Antigens are presented to the effector cells of the adaptive 
immunity by antigen presenting cells. Furthermore, intestinal dendritic cells can 
directly sample the contents of the gut lumen by extending dendrites between 
epithelial cells. 
Although innate and adaptive immunity represent two separate arms of 
immunity, a close relationship exists between them (Palucka and Banchereau 
1999, Bourlioux et al. 2003). The initiation and direction (cellular or humoral) of 
adaptive immunity is influenced by innate immunity, which regulates its direction 
via cytokines, T and B cell co-stimulatory mechanisms and antigen presentation. 
Furthermore, pattern recognition receptors, such as TLRs, in epithelial cells, 
dendritic cells and macrophages are important in bridging the innate and adaptive 
immune responses (for review, see Abreu and Arditi 2004). Continuous formation 
of immunoglobulin (Ig) A in plasma cells in the lamina propria also plays an 
essential role in the protective function of the mucosa (Goodrich and McGee 
1998). This IgA is transported to the luminal side of the mucosa and released into 
the bowel as secretory IgA, where it is able to neutralize potentially pathogenic 
bacteria and viruses.
To summarize, the host's microbiota protects the mucosa against 
colonization and invasion by pathogenic microorgamisms (colonization 
resistance). If this normal microbial habitat is damaged, ecological niches 
are created for pathogens. The intestinal epithelium constitutes a tight 
barrier against pathogens that interact with commensal microbiota. 
Pathogens also crosstalk with the epithelium and modify epithelial 
responses, e.g. to enhance their penetration across the epithelial 
barrier. The immune system constitutes the more specific defence 
against pathogenic bacteria. The innate immunity reacts immediately 
but unspecifically. The adaptive immunity takes longer but is specific 
and keeps memory of previous aggressions. A mild inflammatory state 
is necessary to keep the defence enabled, but the system must remain 
balanced. 
19
2. Helicobacter pylori infEcTion
2.1 gEnEral
Helicobacter pylori (H. pylori) was isolated from gastric mucosa and bacteriologically 
identified in 1982 (Warren and Marshall 1983). Since then, it has been reported 
that ulcer recurrence rates have decreased after the eradication of H. pylori from 
the stomach of peptic ulcer patients (Marshall et al. 1988, Hantschel et al. 1993). 
It has been established that H. pylori infection is a major cause of chronic gastritis 
and peptic ulcer disease. H. pylori was designated a class-I (definite) carcinogen for 
stomach cancer in 1994 after epidemiological investigation by the International 
Agency for Research on Cancer (IARC), a subordinate organization of the World 
Health Organization (IARC 1994). Furthermore, association of primary malignant 
gastric lymphoma with H. pylori has been reported in a large-scale cohort study 
(Parsonnet et al. 1994). However, the role of H. pylori as an obligate pathogen has 
been questioned, and it has been proposed that Helicobacter strains could be part 
of the indigenous microbiota of the human stomach and that H. pylori could have 
both pathogenic and symbiotic features (for reviews, see Blaser 1999, 2006).
2.2 EpidEMiology and TransMission
Approximately half of the world’s population is infected with H. pylori and the 
prevalence shows large geographical variations (for review, see Go 2002). The 
infection is generally acquired during childhood and usually persists indefinitely 
if left untreated. It has been suggested that H. pylori infection rates are associated 
with age, ethnicity, socio-economic status, sanitary environments and lifestyle. In 
Finland, the prevalence of H. pylori infection in children is 6–10% (Ashorn et al. 
1995, Rehnberg-Laiho et al. 1998) and in adults 12–70% (Rehnberg-Laiho et al. 
2001). Prevalence rates generally remain stable in each birth cohort, and thus the 
higher prevalence of infection among the elderly reflects a birth cohort effect with 
higher infection rates in the past (for review, see Rautelin and Kosunen 2004). 
The main reservoir of H. pylori is the human stomach with the most likely mode 
of transmission being person to person (for review, see Vaira et al. 2001). Recent 
epidemiological study suggests that infected mothers are the main source of H. 
pylori infection in their children (Weyermann et al. 2006). 
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2.3 Microbiology and paThogEnEsis
The genus Helicobacter belongs to a subdivision of Proteobacteria, order 
Campylobacterales, family Helicobacteraceae, and consists of over 20 recognized 
species which are all microaerophilic organisms (for review, see Kusters et al. 
2006). Most of the helicobacter species are catalase and oxidase positive, and 
many but not all species are also urease positive. They can be subdivided into two 
major lineages: the gastric Helicobacter species and the enterohepatic (nongastric) 
Helicobacter species. H. pylori is a gram-negative bacterium which usually appears 
spiral-shaped or as a rod with several flagella (Kusters et al. 2006). H. pylori is 
genetically heterogeneous, suggesting a lack of clonality. This results in every 
H. pylori positive subject carrying a distinct strain, although differences within 
relatives may be small (Logan and Walker 2001). 
The pathogenetic mechanisms underlying H. pylori infection are not completely 
understood. H. pylori is sheltered from gastric acidity in the mucus layer. The 
majority of H. pylori in colonized hosts are free-living, but approximately 20% bind 
to gastric epithelial cells (for review, see Peek and Crabtree 2006). Colonization of 
the gastric epithelium by H. pylori is specific in vivo and when H. pylori is found 
in the duodenum, it overlays gastric metaplasia (Steer 1984). Colonization of the 
gastric mucosa by H. pylori evokes local inflammatory responses, which result 
in further mucosal injury but are not able to clear the infection (for reviews, see 
Algood and Cover 2006, Kusters et al. 2006). H. pylori infection thus escapes the 
natural gastrointestinal defences, which allows it to induce chronic infection. It 
has been suggested that the differences in the outcome of the disease are due to 
various virulence factors present in different H. pylori strains. Virulence factors 
help bacteria to invade the host, cause disease and evade host defences. Several 
virulence factors of H. pylori, such as production of urease, a vacuolating cytotoxin, 
and the cytotoxin-associated gene A encoded protein, are associated with injury to 
the gastric epithelium (Dunn et al. 1997, Atherton 1998). 
H. pylori induces a strong inflammatory response in the gastric mucosa 
and results in the expression of a wide spectrum of cytokines, chemokines and 
eicosanoids such as interleukin-8 (IL-8), prostaglandin E2 (PGE2) and leukotriene 
B4
 (LTB4) (for reviews, see Bodger and Crabtree 1998, Nauman and Crabtree 
2004, Kusters et al. 2006). Released from the epithelial cells, these potent pro-
inflammatory mediators promote inflammation and tissue damage locally as well 
as induce migration and activation of neutrophils, macrophages, lymphocytes and 
plasma cells to the site of infection. Closely associated with inflammation and 
cancer (Prescott and Fitzpatrick 2000), the production of PGE2 and LTB4 has been 
shown to be induced in the mucosa of H. pylori positive patients (Wakabayashi et 
al. 1998). Moreover, H. pylori can activate epithelial cell release of arachidonic acid, 
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required for the production of eicosanoids (Pomorski et al. 2001). In accordance 
with promoting chronic inflammation and development of malignancy, H. pylori 
infection also disturbs epithelial barrier functions (Papini E et al. 1998, Terres et al. 
1998, Pelicic et al. 1999) and induces epithelial cell damage (Pai et al. 1999). The 
presence of both local and circulating antibodies can regularly be demonstrated in 
infected patients. All the machinery needed for immune defence thus seems to be 
present, but still, spontaneous recovery is rare. In the absence of treatment, chronic 
H. pylori infection persists for years (Algood and Cover 2006).
H. pylori modulates also the endocrine and physiological functions of the 
stomach (Blaser 2006). Studies have shown that serum pepsinogen (PG) I, sPGII 
and gastrin (G)-17 levels are high in the presence of H. pylori infection related to 
non-atrophic chronic gastritis and that the sPGI, sPGII and sG-17 concentrations 
are found to decrease significantly after a successful H. pylori eradication (Wagner 
et al. 1994, Plebani et al. 1996, Perez-Paramo et al. 1997, Sokic-Milutinovic et 
al. 2005). The determination of sPGI and sPGII, sG-17 and IgG anti-H. pylori 
antibodies has been proposed as a series of non-invasive markers that reflect both 
the morphological and functional status of the gastric mucosa. PGI and II are both 
precursors of pepsin. PGI is a specific marker of corpus secretion capacity, and 
PGII is strongly influenced by gastric inflammation. These precursors are secreted 
into the gastric lumen, and thus only a minimal quantity is measurable from the 
blood. Gastrin is a peptide hormone, produced by endocrine cells in the antrum 
of the stomach, that stimulates acid secretion in the gastric corpus (for review, see 
Plebani 1993). It has been also suggested that H. pylori affects gastric hormones 
that have a role in energy homeostasis, such as leptin and ghrelin (Blaser 2006).
2.4 diagnosis
H. pylori infection can be confirmed by invasive and/or noninvasive methods. 
Invasive tests require esophageal gastroduodenal endoscopy. During endoscopy, 
biopsy specimens of the stomach and duodenum are obtained, and the diagnosis 
of H. pylori is generally made by urease testing, histology and/or culture. All of 
these biopsy-based methods are unpleasant for patients, carry a small but definite 
risk of complications and are subject to sampling error since infection is patchy 
(for reviews see, Logan and Walker 2001, Gatta et al. 2003). Non-invasive tests are 
based on peripheral samples, and the most commonly used ones are the urea breath 
test, fecal antigen tests and serology. There is no single golden standard for the 
diagnosis of H. pylori. In research settings, a combination of at least two methods 
is often applied, as compared to clinical practice, where it is common to use a single 
test (Kusters et al. 2006). Several other tests, such as whole-blood rapid tests, saliva 
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and urine antibody tests, and PCR, are also available, both from biopsy and from 
stool samples (for reviews, see Gatta et al. 2003, Krogfelt et al. 2005).
Common invasive methods
It was noted shortly after its initial isolation that H. pylori (as well as the other 
gastric helicobacters) produced high amounts of urease (Warren and Marshall 
1983). Rapid urease tests detect this enzyme directly in biopsy samples colonized 
with helicobacters (Krogfelt et al. 2005). The tests usually contain 10% urea (either 
in agar, solution or tablet form) and phenol red as an indicator. As the urease 
enzyme of the gastric helicobacter hydrolyzes urea, the pH rises and a color change 
occurs; a positive result can be recorded in minutes or hours. 
For histology, two antral and two corpus biopsies are recommended to avoid 
sampling error (Price 1991). The sensitivity of the histological test depends mainly on 
the experience of the pathologist. The sensitivities and specificities usually achieved 
by histology are both above 95% (Kusters et al. 2006). The benefit of histological 
detection of H. pylori is that it provides histological data on inflammation and 
atrophy, and it also allows the classification of possible gastroduodenal lesions and 
reveals premalignant alterations in the mucosa (Vaira et al. 2002).
The culturing of helicobacters in vitro is very demanding and special culture 
conditions are necessary for it to succeed. These include a microaerobic atmosphere 
(oxygen level of 5–7%) with high humidity, an incubation temperature of 37oC, 
and a rich growth medium (Goodwin and Armstrong 1990, Dunn et al. 1997). 
The benefit of culturing is that it enables antibiotic susceptibility testing of the 
strain involved (Krogfelt et al. 2005).
Common non-invasive methods
In urea breath test (UBT), the patient is given an oral preparation of either 
nonradioisotope carbon-13- (13C-) labeled urea, or radioactive isotope carbon-14- 
(14C) labeled urea (Gatta et al. 2003). In the presence of a H. pylori infection, 
bacterial urease metabolizes the urea to produce labeled carbon dioxide and 
ammonia. The labeled carbon diffuses into the bloodstream and is excreted by the 
lungs. This labeled carbon dioxide can then be measured in the patient's breath 
to determine the presence of H. pylori. The 13C-labeled urea is detected by mass 
spectrometry and the 14C-labeled urea by liquid scintillation. UBT is indicated for 
the initial diagnosis of H. pylori infection and for follow-up of eradication therapy. 
The sensitivity and specificity of UBT are above 95% (Kusters et al. 2006). False 
negatives can result from acid suppression with proton pump inhibitors; therefore, 
acid suppression treatment should be withheld for two weeks prior to testing. In 
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addition, retesting for confirmation of eradication should be done at least four 
weeks after the completion of therapy.
Serological assays measure specific H. pylori IgG and IgA antibodies that can 
determine if an individual has been infected. The sensitivity and specificity of 
these assays generally range between 80 and 90%, depending on the assay used 
(Kusters et al. 2006). In Finland, very high sensitivities (97–100%) and specificities 
(95–99%) have been obtained for detecting H. pylori antibody titers of the IgG 
class (Rautelin and Kosunen 2004). Serological tests are unreliable indicators of 
H. pylori status if a pretreatment serum sample is not available to run in parallel. 
Stool antigen testing identifies active infection and has a sensitivity and 
specificity above 90% (Kusters et al. 2006). In the stool antigen test, a simple 
enzyme-linked immunosorbent assay (ELISA) method is used to detect the presence 
of H. pylori antigens shed in the feces (Gatta et al. 2003). The principle of the stool 
antigen test is that a polyclonal or monoclonal antibody to H. pylori is adsorbed 
to microwells. Diluted patient samples are added to the wells and any H. pylori in 
the fecal sample is bound to the adsorbed antibody. A second H. pylori antibody 
conjugated to peroxidase is added and binds to H. pylori. After unbound material 
is washed off, a substrate is added that reacts with bound peroxidase enzyme to 
produce a yellow color, the intensity of which can be measured to estimate H. pylori 
levels.
2.5 currEnT TrEaTMEnT of H. pylori infEcTion
The spontaneous decline in the prevalence of H. pylori infection in developed 
countries to 10%–15% allows the remaining nonmalignant gastroduodenal 
diseases associated with infection to be addressed with antimicrobial treatment 
(Table 1). Triple therapy, which combines a proton pump inhibitor (PPI) or 
ranitidine bismuth citrate with two antibiotics (clarithromycin and amoxicillin), is 
the current standard of therapy for eradicating H. pylori in Europe (Malfertheiner 
et al. 2002). In Finland, the recommendations follow these guidelines (Finnish 
Gastroenterological Association 2002). A meta-regression analysis of 74 reported 
studies using amoxicillin and clarithromycin plus omeprazole in the eradication of 
H. pylori in adults found an eradication rate of 82% (Schmid et al. 1999). Rescue 
therapies after the failure of first-line and second-line therapies are available, but 
the selection of proper antimicrobial therapy should be made on a case-by-case 
basis and with the help of susceptibility test results (Rautelin and Kosunen 2004). 
However, treatment of infection is challenged by, for example, the rapid rate with 
which the bacteria acquire resistance to the drugs, poor compliance, an excessively 
high bacteria load, impaired mucosal immunity, early re-infection and the presence 
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of intracellular bacteria (for review, see Megraud and Lamouliatte 2003). Thus, 
there is still a need for new compounds that are specific for H. pylori.
Table 1. Suggested therapeutic regimens for eradication of H. pylori infection  
(modified from Finnish Gastroenterological Association 2002, Malfertheiner et al. 2002)
First-line therapy (7 days)
PPI standard dose twice daily (or ranitidine bismuth citrate 400 mg twice daily) 
clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily
Second-line therapy (7 days)
PPI standard dose twice daily
metronidazole 400 mg thrice daily + tetracycline 500 mg 4 times daily 
ranitidine bismuth citrate 400 mg twice daily
Effect of amoxicillin and clarithromycin  
on the ecological balance of gut microbiota
Administration of antimicrobial agents disturbs the ecological balance between 
the host and the normal microbiota (for review, see Sullivan et al. 2001). A 
well balanced microbiota prevent establishment of resistant microbial strains. 
Disturbances in the microbiota depend on the properties of the agents as well 
as on their absorption, route of elimination, and possible enzymatic inactivation 
and/or binding to fecal material. Antimicrobial agents used in eradication of 
H. pylori have been found to cause several disadvantages for the ecological balance 
of gastrointestinal microbiota. 
Amoxicillin is a broad spectrum penicillin derivate. The primary mechanism 
of the action of amoxicillin is to prevent bacterial cell wall synthesis. Several clinical 
studies with amoxicillin supplementation have revealed significant increases in the 
number of enterobacteria and the emergence of resistant enterobacteria strains 
(Brismar et al. 1991, Floor et al. 1994, Stark et al. 1996, Adamsson et al. 1999). 
The dosages have varied between 750 and 2000 mg/day for seven to fourteen days. 
More recently, Lode et al. (2001) have found that amoxicillin administration in 
healthy subjects induced greater counts of enterococci and Escherichia coli strains 
and decreased the number of lactobacilli, bifidobacteria and clostridia. In addition, 
the minimal inhibitory concentration for enterococci was found to increase.
Clarithromycin belongs to the group of macrolide antimicrobial agents. The 
absorption of macrolides is incomplete, and thus high fecal concentrations have 
a strong impact on the balance of the microbiota. Enterobacteria are resistant to 
macrolides, which induces overgrowth of extremely resistant strains. The effect of 
clarithromycin on the composition on intestinal microbiota has been studied in 
only a few clinical trials (Brismar et al. 1991, Edlund et al. 2000, Edlund and Nord 
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2000). The dosage regimens have been from 500 to 1000 mg/day for seven to ten 
days. These studies clearly demonstrate that marked reduction in the number of 
lactobacilli, bifidobacteria and bacteroides is evident in the anaerobic microbiota. 
Reduction in enterobacterial group bacteria and increased numbers of new resistant 
enterobacteria and enterococci strains have also been observed after treatment.
Proton pump inhibitors
Proton pump inhibitors (PPIs) inhibit H+/K+-ATPase via covalent binding to 
cysteine residues of the proton pump, and they remain the most effective available 
therapy to control gastric acid secretion (for review, see Sachs et al. 2006). 
Omeprazole was the first clinically used PPI. Others available include lansoprazole, 
pantoprazole, rabeprazole and tenatoprazole. The main difference between the 
PPIs is the duration of inhibition of gastric acid secretion. However, this has not 
affected H. pylori eradication treatment efficacy when systematically compared 
(for review, see Bazzoli et al. 2002). Omeprazole and lansoprazole remain reference 
PPIs in first-line eradication treatment of H. pylori infection. 
PPIs have shown an excellent safety profile, but there have been concerns that 
the suppression of gastric acid might alter the gastric and duodenal microbiota, 
which could lead to gastric cancer, enteric or other infections and malabsorptions 
(for review, see Williams and McColl 2006). It has been demonstrated that 
elevation of intragastric pH by antisecretory drugs increases bacterial growth both 
in mucosal biopsies and in gastric juice. Moreover, it has been found that H. pylori 
infected patients have greater increases of gastric pH during PPI treatment than 
non-infected patients (Williams and McColl 2006). The overall evidence indicates 
that PPIs are linked with an increased risk of enteric infections (for review, see 
Williams and McColl 2006) and the production of carcinogenic acetaldehyde 
in the upper gastrointestinal tract (Väkeväinen et al. 2000). However, there are 
no convincing results showing production of nitrosamines or interference with 
intestinal digestive processes (Williams and McColl 2006). 
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3. probioTics in  
Helicobacter pylori  infEcTion
3.1 ovErviEw of probioTics
Fermented dairy products and vegetables have been used for thousands of years. 
As early as 1907, Nobelist Elie Metchnikoff attributed the longevity of Bulgarian 
peasants to their consumption of fermented milk products (Metchnikoff 1907). He 
suggested that regular consumption of dairy yogurt may suppress “putrefactive” 
bacteria in the colon. Since then, several definitions have been used to describe 
these probiotics, such as substances that are produced by one microorganism 
and stimulate the growth of other microorganisms (Lilly and Stillwell 1965), live 
microbial feed supplements that beneficially affect the host animal by improving its 
intestinal microbial balance (Fuller 1989), and more recently, live microorganisms 
that, when administered in adequate amounts, confer a health benefit on the host 
(FAO/WHO 2002). 
The most commonly used organisms in probiotic products belongs to 
Lactobacillus sp., and Bifidobacterium sp. (Saxelin et al. 2005). Other organisms 
have also been used including Bacillus sp., and yeast such as Saccharomyces boulardii. 
Probiotic products are commercially available in different formulations with and 
without prebiotics such as fructo- and galacto-oligosaccharides. The concentration 
of probiotics in research trials and in food or other products varies greatly, and 
there are no international standards regarding the levels of bacteria required (for 
review, see Parvez et al. 2006).
Several proposed health effects of probiotics are summarized in Figure 2. The 
primary clinical interest in the application of probiotics has been in the prevention 
and treatment of gastrointestinal infections and diseases (Parvez et al. 2006). The 
use of probiotics for controling chronic gastrointestinal inflammatory diseases, 
such as ulcerative colitis and pouchitis, has also received considerable attention. 
Moreover, the consumption of probiotics has been linked to improvement of a wide 
variety of health conditions, including lactose intolerance, high cholesterol and 
rheumatoid arthritis. Also, there is evidence of beneficial effects of probiotics with 
respect to the development of dental caries, allergy and cancer (Parvez et al. 2006). 
The general mechanisms by which probiotics may have an effect can be divided 
into three broad categories: normalization of microbiota, modulation of immune 
response, and metabolic functions. However, the molecular details behind these 
mechanisms remain mostly unknown (Marco et al. 2006).
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3.2 clinical sTudiEs
The role of probiotics in the treatment of H. pylori infection is increasingly 
documented as a complement or alternative to antibiotics, and thus having the 
potential to decrease the use of antibiotics.
Probiotics as a complement to antibiotics may have the potential to reduce the 
adverse events of triple anti-Helicobacter treatment and to improve the eradication 
rate (Table 2). The first study provided evidence that L. acidophilus LB improved 
the eradication rate significantly in the probiotic group (Canducci et al. 2000). 
However, in this study the supplementation did not alleviate the adverse effects of 
the anti-Helicobacter treatment. In contrast, Armuzzi et al. (2001a, 2001b) reported 
in two separate studies that L. rhamnosus GG was able to reduce the occurrence of 
adverse effects, such as diarrhea, taste disturbance, nausea and bloating. The latter 
of these two studies was conducted in double-blinded fashion. Moreover, Sheu et al. 
(2002) reported in an open and uncontrolled trial that the L. acidophilus La5 and 
Figure 2 Summary of various health effects of probiotics (modified from Parvez 2006).  
SCFA, short-chain fatty acid
Control of irritable  
bowel syndrome
Control of imflammatory 
bowel disease
Supression of  
endogenous pathogens
Prevention and alleviation 
of food allergy in infants
Stregthening innate  
immunity
Lowering serum  
cholesterol
Improvement of lactose 
tolerance
Suppression of  
exogenous pathogens









Supply of SCFA and 
vitamins to colonic 
epithelium
Lower level of toxigenic 










B. lactis Bb12 containing yogurt (AB-yogurt) was able to increase the eradication 
rate and also decrease several side-effects of the triple therapy. Administration of 
L. rhamnosus GG, Saccharomyces boulardii or combination of L. acidophilus and 
B. lactis for two weeks also decreased adverse events during the triple treatment 
(Cremonini et al. 2002). However, the effect of probiotic supplementation seemed 
independent of the probiotic species used. Tursi et al. (2004) also recently found 
that a 10-day quadruple anti-Helicobacter therapy with L. casei ssp. casei DG 
supplementation significantly increased the eradication rate in patients after 
failure of first-line eradication treatment. Similarly, L. acidophilus La5 combined 
with B. lactis Bb12 improved the second-line rescue therapy in patients with H. 
pylori resistance (Sheu et al. 2006). There are two studies conducted with dyspeptic 
children. In the first, L. casei DN-114 001 containing fermented milk product was 
effective in increasing the eradication rate of standard triple treatment (Sykora et 
al. 2005). More recently, L. reuteri was found to alleviate eradication treatment 
associated adverse effects, but it was not able to increase the eradication rate 
(Lionetti et al. 2006).
There are not many studies on the attenuation of microbiota disturbances 
with probiotics following an anti-Helicobacter triple treatment. In a pilot study, 
Madden et al. (2005) found that probiotic combination including two strains 
of L. acidophilus (CLT60 and CUL21) and two strains of B. bifidum (CUL17 
and B. bifidum Rhodia) stabilized the number of facultative anaerobes. Later the 
same probiotic product was able to reduce the amount of antibiotic resistance 
among enterococci and reduce the disruption of the enterobacterial component in 
the re-growth population (Plummer et al. 2005). However, despite the probiotic 
supplementation, the microbiota in both studies was susceptible to the effects of 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































Probiotics as an alternative to antimicrobials have also been the focus 
of several studies (Table 3). Administration of culture supernatant or fermented 
milk containing the strain of L. acidophilus La1 decreased H. pylori urease 
activity, measured by 13C-UBT in adults (Michetti et al. 1999) and in children 
(Cruchet et al. 2003), and also in two other trials by histological analysis (Felley 
et al. 2001, Pantoflickova et al. 2003). Furthermore, in the latter two studies, a 
decrease in H. pylori infection-associated inflammation was evident. However, the 
regular intake of L. acidophilus ( johnsonii) La1 did not eradicate H. pylori in any 
of the studies. Sakamoto et al. (2001) found L. gasseri OLL2716 to be effective 
in suppression of H. pylori and reduction in gastric mucosal inflammation as 
measured by 13C-UBT and assays of serum pepsinogen I. In their study, 31 subjects 
with H. pylori infection ingested yogurt containing L. gasseri daily for an eight-
week period. L. casei was also shown to inhibit H. pylori growth and to reduce 
13C-UBT values (Cats et al. 2003). Similar effects on growth of H. pylori were 
reported for yogurt containing L. acidophilus La5 and B. lactis Bb12 and consumed 
for 6 weeks by 59 human volunteers (Wang et al. 2004). However, not all clinical 
trials have shown effectiveness. In one open study, 27 H. pylori infected volunteers 
received yogurt containing three Lactobacillus spp. and one commercial starter 
culture for one month (Wendakoon et al. 2002). At the end of the trial 13C-UBT 
values remained positive in 26 of the 27 subjects. However, this study used strains 
that were not proven probiotics.
Studies on the effects of synbiotics (probiotics combined with prebiotics) on 
H. pylori infection are very scarce, and to my knowledge, no clinical studies on 
prebiotics exist. A randomized, open, eight-week study investigated the effects 
of L. acidophilus LB in comparison with antibiotics and with the synbiotic 
combination of probiotic yeast Saccharomyces boulardii with inulin (Gotteland et 
al. 2005). The eradication rate was slightly better in the S. boulardii combined 
with inulin study group.
To summarize, these observations suggest that consumption of certain 
strains of probiotics may be useful in combating H. pylori infection as 
a complement to the first-line or the second-line eradication therapy. 
Generally, complete eradication of H. pylori without anti-helicobacter 
therapy has not succeeded. However, regular consumption of probiotic 
products with specific strains as an alternative to antibiotics may have 









































































































































































































































































































































































































































































































































































































































































































































































































































































































Various probiotics have shown favorable effects in animal models of H. pylori 
infection (Table 4). The first two studies presented a highly protective and 
therapeutic effect of oral administration of L. salivarius on H. pylori infected 
gnotobiotics (animals that have been raised in germ-free environments, or contain 
only specific germs) BALB/c mice model (Kabir et al. 1997, Aiba et al. 1998). 
Similarly, Coconnier et al. (1998) reported that L. acidophilus strain LB was able 
to protect against H. pylori infection in conventional mice. Inhibition of stomach 
colonization of H. felis SC1 (a bacterium closely related to H. pylori) was observed 
and no evidence of gastric histopathological lesions was found. Recently, probiotic 
combination containing L. acidophilus R0052 and L. rhamnosus R0011 reduced 
the effects of H. pylori infection in a C57BL/6 mice model of infection through 
reducing H. pylori colonization and alleviating H. pylori-induced inflammation 
of the stomach (Johnson-Henry et al. 2004). Also, the same probiotic preparation 
has proven effective in a Mongolian gerbil model of H. pylori infection via its 
attenuating effect on the H. pylori colonization, the mucosal inflammation, and 
the impairment of the gastrin-somatostatin link (Brzozowski et al. 2006). Studies 
by Sgouras et al. (2004, 2005) in a C57BL/6 mice model demonstrated that 
L. casei strain Shirota and L. johnsonii La1, both administered in drinking water, 
attenuated H. pylori infection-induced gastric mucosa inflammation. However, 
only L. casei strain Shirota was able to down-regulate the colonization of H. pylori to 
gastric mucosa. Moreover, L. gasseri was found to decrease clarithromycin resistant 
H. pylori colonization (Ushiyama et al. 2003).
Development of an effective vaccine is also an interesting area in the prevention 
of H. pylori infection. However, the ability of recombinant Lactobacillus or other 
probiotics to be used as an antigen-delivery vehicle to induce protective immune 
responses has rarely been studied. In the study by Lee et al. (2001), Lactococcus 
lactis producing cytoplasmic urease B was shown to be unable to induce protection 
against H. pylori in a mouse model. In contrast, a recombinant L. plantarum strain 
producing H. pylori urease B subunit was found to successfully induce a partial 

























































































































































































































































































































































































































































































































































































































































































































































































3.4 possiblE MEchanisMs of probioTic acTion
The mechanisms of probiotic action on H. pylori infection are unclear, but there 
are a number of proposed or hypothesized possibilities from in vitro studies of host 
intestinal epithelial or immune cell responses to probiotic strains. A summary of 
these possible mechanisms is provided in Figure 3 and described here in more 
detail. 
Generally, probiotics such as lactic acid bacteria and bifidobacteria are able to 
produce organic acids, hydrogen peroxide and carbon dioxide to inhibit potential 
pathogens. In addition, many probiotics have been found to produce more defined 
antimicrobial substances (for review, see Servin 2004). Coconnier et al. (1998) 
found that the anti-Helicobacter substance(s) in the L. acidophilus LB strain were 
different from lactic acid. Also, L. johnsonii La1, shown to be beneficial in several 
clinical and experimental studies in treatment of H. pylori infection, has been 
found to release non-bacteriocin antimicrobial substances (Bernet-Camard et al. 
1997). Furthermore, some Bifidobacterium strains have been found to release heat-
stable proteinaceous antimicrobial compounds against H. pylori in vitro (Collado 
et al. 2005). 
The anti-infective activity of probiotics may also partly be due to coaggregation 
with pathogens (Cesena et al. 2001), whereby pathogens are exposed to high doses 
of potential growth-inhibiting factors produced by probiotics. One mechanism 
proposed recently is that the L. johnsonii La1 expresses cell-surface associated 
La1GroEL protein, and its recombinant variant, expressed in Escherichia coli, is 
able to induce aggregation of H. pylori, but not of other intestinal pathogens. The 
L. johnsonii La1 was also shown to have pro-inflammatory activity, thus favoring 
the activation of intestinal immunological defences (Bergonzelli et al. 2006). 
Adhesion of pathogens can also be inhibited by steric hindrance, where a large 
number of beneficial bacteria may cover receptor sites in a non-specific manner, 
or by competing for specific carbohydrate receptors that would otherwise be 
available to pathogens. Several probiotic species, such as L. salivarius, L. gasseri 
and L. acidophilus, have shown growth inhibition or anti-adhesion capacity against 
H. pylori in a gastric epithelial cell model (Midolo et al. 1995, Coconnier et al. 
1998, Lorca et al. 2001, Mukai et al. 2002, Nam et al. 2002, Sgouras et al. 2004, 
Tsai et al. 2004). 
Mukai et al. (2002) have also examined competition in the binding of nine 
L. reuteri strains and H. pylori to gangliotetraosylceramide (Asialo-GM1) and 
sulfatide, which are putative glycolipid receptor molecules of H. pylori, and identified 
a possible sulfatide and Asialo-GM1 binding protein of the two L. reuteri strains 
(JCM1081 and TM105). Moreover, several probiotics are able to inhibit adhesion 
of pathogenic microorganisms by modifying the glycosylation state of the receptor 
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in epithelial cells using soluble factor(s) excreted by the probiotics (for review see, 
Servin 2004).
Several probiotic bacteria have been shown to prevent and repair mucosal 
damage by inhibiting damage to tight junction proteins (Montalto et al., 2004). 
The probiotic strains prevented the pathogen-associated disruption of the 
cytoskeletal and tight junction proteins in the epithelial cells, thus improving the 
mucosal barrier function and preventing failure in the secretion of electrolytes 
(Resta-Lenert and Barrett 2002, 2003). Regular ingestion of live L. rhamnosus GG 
protected the integrity of gastric mucosa, as evaluated by the sucrose permeability 
test, against alterations by indomethacin (Gotteland et al. 2001), thus suggesting 
at least transient residence in the human stomach and functional effectivity. 
Probiotic combination of VSL#3, which is a mixture of eight different strains 
(L. acidophilus, L. delbruckii ssp. bulgarus, L. casei, L. plantarum, Bifidobacterium 
longum, B. infantis, B. breve and Streptococcus thermophilus), and soluble factors of 
L. rhamnosus GG were able to induce specific heat shock proteins, known for their 
ability to maintain actin cytoskeleton integrity (Petrof et al. 2004, Tao et al. 2006). 
Further, a novel mechanism of maintaining barrier function was identified by Yan 
and Polk (2002). These investigators showed that L. rhamnosus GG was able to 
prevent cytokine-induced apoptosis in intestinal epithelial cell models through the 
inhibition of a TNF-induced activation of the proapoptotic p38/mitogen-activated 
protein kinase. 
Several reports suggest that probiotics are able to differentially modulate innate 
immune responses in both anti-inflammatory and pro-inflammatory directions. 
Probiotic bacteria can bind to recognition receptors, such as TLRs expressed on 
the surface of epithelial cells, and thus trigger a cascade of immunological defence 
mechanisms (for review, see Saxelin et al. 2005, Sartor 2005). TLR4 recognizes 
lipopolysaccharide and gram-negative bacteria, while TLR2 recognizes a variety of 
microbial components, such as peptidoglycan and lipoteichoic acids, from gram-
positive bacteria (for review, see Abreu 2003, Matsuguchi et al. 2003, Takeda et al. 
2003). Oral CpG delivery was found to reduce significantly H. pylori colonization 
in a mouse model of H. pylori infection (Raghavan et al. 2003). Thus bifidobacteria, 
which generally contain DNA with high GC contents and hence a high fraction of 
unmethylated CpG sequences, could affect the immune system by interacting with 
TLR9, triggering the production of pro-inflammatory cytokines and promoting 
T helper cell -1 response to reduce H. pylori colonization (Saxelin et al. 2005). 
The possible mechanism underlying this effect, when regarding concomitant 
CpG administration, is enhanced mucosal cytokine production and immune 
stimulation.
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Also, enhancement of secretory IgA production on intestinal epithelium may 
have a role in pathogenic bacterial defence (Viljanen et al. 2005c). Furthermore, it 
was shown recently that L. rhamnosus GG is able to antagonize H. pylori induced 
TNF-α production by murine macrophages in vitro by a contact-independent 
mechanism (Peña et al. 2003). Probiotics could down-regulate virulence genes in 
pathogenic bacteria. Furthermore, mucins, high-molecular-weight glycoproteins 
secreted by epithelial cells, may also bind to pathogens, thereby inhibiting their 
adherence to epithelial cells. Moreover, release of gastric mucin is found to be 
down-regulated by H. pylori (Byrd et al. 2000). Probiotics could thus interfere with 
the actions of H. pylori, since several strains, for example Lactobacillus plantarum 
299V and L. rhamnosus GG, have induced mucin gene expression (Mack et al. 
1999, Mattar et al. 2002, Mack et al. 2003). 
Various microorganisms have been described as binding the dendritic cell 
(DC) receptor specific intercellular adhesion molecule 3-grabbing nonintegrin 
(DC-SIGN), including H. pylori. It has been suggested that distinct ligands 
from different microorganisms show different functional effects. Ligation of 
DC-SIGN by H. pylori induces increased levels of IL-10 in human DCs and a 
shift toward Th2 development (Bergman et al. 2004). In contrast, probiotics, 
specifically L. reuteri and L. casei, do not induce increased levels of IL-10 from 
DCs. Probiotics were also found to induce regulatory T cell development through 
modulation of DC function (Smits et al. 2005). It is currently unclear which 
different signals are transduced by DC-SIGN ligation. Probiotic bacteria such 
as L. rhamnosus induced maturation of dendritic cells, but resulted in a different 
cytokine profile than pathogenic bacteria (Braat et al. 2004). The probiotic 
product VSL#3 upregulated IL-10 and down-regulated IL-12 production by 
dendritic cells derived from human blood and the lamina propria. The main 
effect of this combination is found to come from bifidobacteria (Hart et al. 
2004). Also, the Bifidobacterium strain's DNA from the same combination, 




Data on the safety of probiotics suggest that probiotic therapy is generally considered 
safe (Boyle 2006, Hammerman et al. 2006). Lactobacilli and bifidobacteria are 
part of normal gastrointestinal microbiota, and systemic infections with these 
bacteria may thus occur naturally, unrelated to the ingestion of probiotics. 
Accordingly, increased probiotic use of L. rhamnosus GG in Finland has not 
led to an increase in Lactobacillus bacteremia (Salminen et al. 2002) and is also 
regarded as safe in immunocompromised HIV-infected patients (Salminen et al. 
2004). Bifidobacteria are found to be even safer because no cases of sepsis related 
to probiotic ingestions have been reported. Propionibacteria are also regarded as 
Figure 3 Schematic presentation of possible mechanisms of probiotics to interfere with H. pylori induced 
functional effects (modified from Marco et al. 2006). Probiotics potentially interfere with H. pylori by 
production of antimicrobial substances (1), inducing aggregation (2) and competing with host-cell-
binding sites (3). They could modulate inflammatory responses (4) and strengthen the mucosal barrier (5). 
Probiotics with a high fraction of CpG sequences can possibly reduce H. pylori colonization (6). Differential 
modulation of cytokine production recognised by Toll-like receptors (TLR) (7), enhancement of secretory 
immunoglobulin A (Ig) A production (8) and decreased tumor necrosis factor (TNF)-α production by 
macrophages could have a role in H. pylori infection (9). Probiotics could down-regulate the production of 
virulence factors of H. pylori (10) and induce mucin release from epithelial cells (11). They could compete 
with H. pylori in binding to dendritic cell (DC) receptor specific intercellular adhesion molecule 3-grabbing 
nonintegrin (SIGN) (12) and modulate DC function and regulatory T (Tr) cell development (13). B, B cell 
(plasma cell); DC, dendritic cell; Hsp, heat shock protein; IL, interleukin; NF, nuclear factor; Th, T helper cell
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safe to use, mainly because of their long history of safe use in Emmental cheese 
manufacturing. P. freudenreichii ssp. shermanii has consequently been proposed for 
“Qualified Presumption of Safety” status by the European Food Safety Authority 
(EFSA 2007). 
Safety considerations regarding antimicrobial resistance are also recognized 
among probiotics. There are questions about the possibility of resistance transfer 
both from probiotics to pathogenic bacteria and from commensal microbiota to 
probiotics (for review, see Courvalin et al. 2006). Probiotics strains are generally 
susceptible to the majority of antibiotics, but a recent clinical study shows that 
they can survive gastrointestinal transit quite well during antibiotic treatment 
(Saarela et al. 2007). However, this did not lead to transfer of resistance genes 
from original microbiota to the ingested probiotics. In any case, different strains of 
probiotics have different safety profiles, which should be taken into account, and 
generalizations concerning all probiotics should be avoided (Hammermann et al. 
2006).
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The aim of the present study was to discover the role of probiotics in the treatment 
of Helicobacter pylori infection and to evaluate the mechanisms of action.
The specific aims of this study were:
To clarify the importance of probiotics as an adjuvant to the current recom-
mended treatment of H. pylori infection (Study I).
To investigate the effects of H. pylori eradication treatment and probiotics on 
intestinal microbiota alterations during the treatment of H. pylori infected sub-
jects (Study II).
To find out the recovery and the effects of probiotics in gastric and duodenal 
mucosa in H. pylori infected and uninfected patients (Study III)
To characterize the actions of probiotics in H. pylori infected intestinal epithe-





aiMs of ThE sTudy
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The subjects, materials and methods are described in detail in the original studies. 
A summary of the subjects is shown in Table 5. 
1. sTudy dEsigns and subjEcTs
Studies I and II were conducted in a randomized, double-blind, placebo-controlled 
design. All participants received a seven-day triple therapy [lansoprazole (30 mg), 
clarithromycin (500 mg) and amoxicillin (1 g) twice daily; Helipak K, Orion 
Pharma, Espoo, Finland] and were randomized to receive either a milk-based 
drink containing a total of 1x109 colony-forming units (CFU) / ml of probiotics or 
the same drink without the probiotics. Randomization was carried out according 
to a computer-generated blocked randomization list using a block size of four. The 
subjects consumed the drink twice a day during the eradication treatment and once 
a day for the following three weeks. For one month before the study and during 
the intervention (4 weeks) and the follow-up period (6 weeks), all other probiotic 
products were forbidden. Exclusion criteria were antibiotic treatment during the 
previous two months, the use of H2-receptor antagonists, bismuth or proton pump 
inhibitors (PPI) during the previous two weeks, H. pylori eradication treatment 
during the previous five years, use of probiotic products during the previous month, 
gastric surgery, any diagnosed chronic gastrointestinal disease, allergies to drugs 




A paired study design in which each subject served as his/her own control was 
used in Study III. The study interventions lasted a total of 56 days (8 weeks) ± 3 
days. All patients underwent gastroduodenoscopy, and biopsy samples were taken 
by an experienced endoscopist. The probiotic preparation intake was started on the 
morning after the first endoscopic examination, and the last probiotic drink was 
taken on the evening of the day before the second endoscopic examination. The 
volunteers fasted over the night preceding each gastroduodenoscopy. Exclusion 
criteria were upper gastrointestinal tract lesions, a history of upper gastrointestinal 
surgery, chronic severe atrophy in the gastric or duodenal mucosa and were 
otherwise similar to Studies I and II. All the subjects were asked to abstain from 
commercial products containing probiotic microorganisms two weeks prior to the 
intervention and during the intervention. 





Description of study groups
i H. pylori infected 47 18/29 56 (24–69) H. pylori infected with 
triple eradication treatment
ii Total 










H. pylori infected with triple eradication 
treatment and uninfected controls
iii Total 











H. pylori infected and 
uninfected patients referred for  
gastroduodenoscopy
2. EThics
All subjects gave their written informed consent (Studies I, II, III). The Ethics 
Committee of the Joint Authority for the Hospital District of Helsinki and 
Uusimaa approved the protocols for Studies I and II. The Ethics Committee of the 
Pirkanmaa Hospital District (Tampere University Hospital, Tampere, Finland) 
and the research licensing committee at the City of Tampere approved Study III.
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3. probioTic producTs  
and bacTErial sTrains 
Probiotic products (Studies I, II, III)
The probiotic products consisted of four different strains: Lactobacillus rhamnosus 
GG (ATCC 53103), Lactobacillus rhamnosus LC705 (DSM 7061), Propionibacterium 
freudenreichii ssp. shermanii JS (DSM 7076), and Bifidobacterium breve Bb99 in 
Studies I and II or B. lactis Bb12 in Study III (Chr. Hansen, Horsholm, Denmark). 
This probiotic combination was used because LGG has been found beneficial as a 
supplement in H. pylori eradication treatment (Armuzzi et al. 2001a, 2001b), and 
LC705 and Propionibacterium freudenreichii ssp. shermanii JS (PJS) have shown 
anti-pathogenic effects (Suomalainen and Mäyrä-Mäkinen 1999, Hatakka et al. 
2007). Moreover, Bb12 has shown beneficial effects in H. pylori infection in vitro 
and in vivo (Cremonini et al. 2002, Wang et al. 2004, Sheu et al. 2006). In Studies 
I and II, two batches of the milk-based drinks were used during the clinical study to 
maintain product quality and to prevent loss of microbial activity in the products. 
In Study III, several batches of the drink were used during the study period. The 
daily dose of the drink was 250 ml, and the amount of each probiotic bacteria 
in the drink was on average 107 CFU/ml. Microbial quality of the products was 
regularly assessed during the interventions by microbial plating methods.
Bacterial cultures (Study IV)
The lyophilized H. pylori was grown on Brucella agar enriched with horse serum at 
+37°C for 4 to 6 days under microaerophilic conditions. The bacterial suspension 
was stored at -80°C. Before the experiments, H. pylori was subcultured twice on 
Brucella agar as described above. For the experiments, the bacteria were aseptically 
harvested and suspended in Dulbecco's modified Eagle's medium (DMEM) and 
kept under microaerophilic conditions until use. H. pylori concentrations were 
determined by plating methods. 
Both L. rhamnosus GG (LGG) and L. rhamnosus LC705 (LC705) were grown 
in de Man, Rogosa and Sharpe broth at +37°C under aerobic conditions for 
18–20 h. PJS was grown in broth for propionibacteria strains at +30°C for 48 h. 
Bifidobacterium breve Bb99 (Bb99) was grown in de Man, Rogosa and Sharpe broth 
broth enriched with 1% L-cysteine hydrocloride monohydrate under anaerobic 
conditions at +37°C for 24 h. E. coli strain DH5α was grown in Luria-Bertani 
broth under aerobic conditions at +37°C for 18 h. All probiotic bacteria were 
subcultured three times before harvesting for the experiments. Harvested bacteria 
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were centrifuged, washed with phosphate buffered saline (PBS) and resuspended at 
109 CFU/ml, as estimated by plating methods, in DMEM. 
Table 6. Summary of bacterial strains used in study IV.
Srain Origin
L. rhamnosus GG, ATCC 53103 Isolated from adult human
L. rhamnosus LC705, DSM 7061 Isolated from milk
Propionibacterium freudenreichii ssp. shermanii JS, 
DSM 7076
Isolated from cheese
Bifidobacterium breve Bb99, 
DSM 13692
Isolated from a 3-month-old breast-fed infant
Helicobacter pylori, NCTC 11637 Isolated from human, gastric antrum (cytotoxin-as-
sociated gene A -positive strain)
Escherichia coli, DH5α General laboratory strain
4. METhods
4.1 H. pylori infEcTion assEssMEnT
13C-urea breath test (Studies I, II, III)
After an overnight fast, subjects gave duplicate breath samples before and ten 
minutes after swallowing the 13C-labeled urea tablets with a glass of water (Diabact 
UBT, Diabact AB, Uppsala, Sweden). The breath samples were analyzed using 
isotope ratio mass spectrometry, and delta over baseline values over 4 per mil (‰) 
was considered confirmation of a positive H. pylori infection.
Serological tests (Studies I, II, III)
For each volunteer (studies I and II), rapid whole-blood tests (Pyloriset Screen 
II, Orion Diagnostica, Espoo, Finland, and Biocard Helicobacter pylori IgG, 
AniBiotech Ltd, Helsinki, Finland) were carried out on fingertip blood according 
to the manufacturers’ instructions. A blood sample was obtained from each subject, 
and the sera were stored at -20°C until analysis. Serum samples collected at the 
baseline were determined by an in-house EIA, together with samples collected 
at 4 months after therapy, for H. pylori antibodies of the IgG and IgA classes. 
As an indicator of successful eradication therapy, antibody titers of the IgG class 
had fallen by more than 40% from the pre-treatment level (Studies I and II). In 
Study III, serum samples were stored before analysis at -20 °C for determination of 
IgG-H. Pylori levels by ELISA according to the manufacturer's instructions (Biohit 
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Ltd., Helsinki, Finland). The normal reference value for IgG-H. Pylori titers was 
<44 IU.
Histology (Study III)
The presence and colonization of H. pylori infection was determined by modified 
Giemsa staining. Gastric biopsies (two from the antrum and two from the corpus) 
were obtained from each patient for analysis. Biopsy samples were fixed in 4% 
paraformaldehyde, stained with hematoxylin-eosin and Giemsa, and subsequently 
evaluated by an experienced pathologist.
Biopsy-based rapid urease test (Study III)
A rapid urease test was performed according to the manufacturer’s instructions 
(Biohit) on at least one biopsy sample from either the gastric antrum or the corpus. 
The biopsy sample was placed on gel containing urea and phenol red as an indicator. 
The color change was monitored after 2 and after 30 minutes.
4.2 QuEsTionnairEs
Treatment related symptoms (Study I)
The participants recorded their daily symptoms in a standardized questionnaire, 
modified from de Boer et al. (1996), at baseline and during the entire intervention 
period, five weeks in all. Baseline symptoms were recorded daily for one week 
before the intervention. The following symptoms were included in the total 
symptom score: epigastric pain, bloating, flatulence, taste disturbance, loss of 
appetite, nausea, vomiting, heartburn, constipation, and skin rash. The symptoms 
were scored from 0 to 3: absent (0), mild (1), moderate (2) and severe (3). 
Bowel function (Study I)
The participants also filled in a daily questionnaire on their bowel function 
(frequency and consistency). Stool consistency was graded from hard (0) to watery 
(5). Diarrhea was defined as at least three watery or loose stools per day for a 
minimum of two consecutive days. 
Probiotic drink consumption (Studies I, II, III)
Compliance regarding consumption of the study drink was evaluated by 




For FISH analysis, fecal samples were diluted, homogenized and centrifuged 
to remove the coarse material. The supernatant was mixed 1:4 with fresh 4% 
paraformaldehyde and fixed. The fixed bacterial cells were collected, washed and 
resuspended in PBS with added 94% ethanol. The cell suspension was diluted 
1:20 with hybridization buffer and the fluorescent probe was added (Table 7). 
Hybridization was carried out overnight; washing and filtering were performed 
according to Franks et al. (1998). Filters were mounted on a slide with AntiFade 
reagent and covered with a glass. Cells were counted visually with an epifluorescence 
microscope. DAPI dye (4',6-diamidino-2-phenylindole) was used for the detection 
of total bacteria counts.
Table 7. Cy3-labeled oligonucleotide probes used in FISH analysis.
Bacteria group Probe Reference
Bacteroides fragilis Bfra602 Franks et al. 1998
Bacteroides distasonis Bdis656 Langendijk et al. 1995
Bifidobacteria Bif164 Franks et al. 1998
Clostridium histolyticum Chis150 Harmsen et al. 1999
Eubacterium rectale - Clostridium coccoides Erec482 Suau et al. 2001
Lactobacilli and enterococci Lab158 Harmsen et al. 1999
Faecalibacterium prausnitzii Fprau0645 Suau et al. 2001
The concentration of LGG in the feces was analyzed with real-time quantitative 
PCR (Study II). A strain-specific quantitative PCR method was used for LGG 
using LightCycler FRET technique (Halme et al. 2002). DNA for PCR was 
isolated from the feces using a Wizard® Genomic DNA purification kit following 
the manufacturer’s instructions (Promega, Madison, WI, USA), except that 
lysozyme and mutanolysin were used during the 1 h incubation at +37°C. The 
standard DNAs for quantification were isolated from the dilutions of the known 
concentrations (CFU/ml) of LGG. The concentration of LGG in the culture was 
determined by plating, and a tenfold dilution series was made for DNA isolation. 
The isolation steps were the same for the standards and for the fecal DNAs.
For quantification of the PJS strains, fecal samples were melted and ten-fold 
dilutions were made in Wilkins-Chalgren broth (study II). The dilutions were 
plated on buffered propionibacterium agar and incubated anaerobically at +30°C 
for seven days. Typical PJS-like colonies, light yellow in color, were counted and 
the cell morphology was verified by microscopy. Isolates were further identified 
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by biochemical tests (nitrate reduction and lactose fermentation) and random 
amplification of polymorphic DNA analysis. PCR amplification was performed 
with a DyNAzyme® DNA Polymerase kit (Finnzyme, Espoo, Finland) according 
to the instructions of the manufacturer. PCR was performed straight from a fresh 
colony. PJS was used as a positive control in all the analyses. The preliminarily 
count of the amount of PJS strains was corrected according to RAPD-verified PJS 
isolates.
In Study III, a strain-specific real-time PCR assay was developed for 
quantification of each strain using a LightCycler FRET technique similarly to that 
in Study II (Halme et al. 2002, Mikkola et al. 2006), except that the concentration 
of Bb12-strain was determined with a B. lactis-specific primer pair (Ventura et al. 
2001) with the SYBR Green and melting curve analysis method. Each volunteer’s 
two biopsy samples from the same locus were combined and immersed, vortexed 
vigorously and cooled on ice. Bacterial genomic DNA was extracted from the biopsy 
and fecal samples, and pure cultures were isolated with the Wizard® genomic DNA 
purification kit (Promega) following the manufacturer’s instructions. In addition, 
lactic acid bacteria (LAB) of the genera Lactobacillus, Pediococcus, Leuconostoc, and 
Weissella were analyzed with group-specific primers using SYBR Green in real-
time PCR to confirm successful DNA isolation (Walter et al. 2001). The standard 
curves used for quantification of the strains consisted of a series of 10-fold dilutions 
of the target species genomic DNA.
Culture methods
For microbial populations analyzed by cultivation (Study II), the fecal samples 
were thawed in an anaerobic chamber and diluted 1:10 with Wilkins-Chalgren 
medium. The mixture was homogenized and dilutions were plated on agar plates. 
Total aerobic bacteria were cultivated on BHI agar and anaerobic bacteria on 
the same agar reduced before used. Enterobacteria were grown on Violet red bile 
glucose agar. YGC agar was used for yeast and molds. Propionic acid bacteria were 
grown on buffered propionic agar. 
4.4 Morphological and funcTional sTaTus  
of ThE gasTroduodEnal Mucosa
Histological evaluation of gastric and duodenal biopsies 
Six gastric biopsies (two from the antrum, two from the corpus and two from 
the duodenum) were obtained from each patient for histological analysis. Biopsy 
samples were fixed in 4% paraformaldehyde, stained with hematoxylin-eosin and 
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subsequently evaluated by an experienced pathologist. The degree of inflammation 
present in the histological specimens was classified according to the updated Sydney 
system (Dixon et al. 1996). A grading scale from 0 to 3 (none, mild, moderate, 
or severe) was assigned for four histological variables: chronic inflammation 
(mononuclear cell infiltration), activity (polymorphonuclear neutrophil infiltration), 
intestinal metaplasia, and glandular atrophy for the antrum and corpus separately.
Determination of serum pepsinogens and gastrin-17
Serum samples were stored before analysis at −20°C for determination of serum 
pepsinogen (sPG) I, sPGII and gastrin-17 levels by ELISA, according to the 
manufacturer's instructions (Biohit). Normal reference values were as follows: 
sPGI: 25–100 μg/l; sPGII: 2–10 μg/l; and sG-17: 2.5–7.5 pmol/l.
4.5 cEll culTurE METhods
Caco-2 cell culture 
Caco-2 cells (HTB 37) obtained from the American Type Culture Collection 
(Manassas, VA, USA) were cultured at +37°C in DMEM supplemented with 10% 
fetal calf serum (Biological Industries, Kibbutz Beit Haemek, Israel) and antibiotics 
(penicillin G 100 U/ml, amphotericin B 250 ng/ml, and streptomycin 100 μg/ml, 
GIBCO). Cells were seeded (1x105 cells/cm2) on microporous inserts as presented 
in Figure 4 (Transwell, Corning Costar, Corning, NY, USA) or on 12-well plates 
(Corning Costar). Confluent monolayers were differentiated for 15 to 21 days and 
were cultured in medium without antibiotics for 24 h before each experiment.
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H. pylori adhesion
Adhesion of H. pylori was analyzed using a modified version of the method used by 
Nozawa et al. (2002). Briefly, Caco-2 cells were differentiated on standard 96-well 
plates (Nalge Nunc International, Naperville, IL, USA) at an initial density of 
1x105 cells/cm2. Cell monolayers were pretreated with the individual probiotics or 
their combination at desired concentration in fresh culture medium at +37°C for 1 
h. Culture medium was then replaced with a 100 μl aliquot of H. pylori at desired 
concentrations in fresh culture medium. The plates were incubated at +37°C for 
90 min and washed twice with PBS to remove the non-adherent H. pylori. Cells 
with adherent H. pylori were fixed and after three washes with PBS, 70 μl of rabbit 
anti-H. pylori antibody (Dako A/S, Glostrup, Denmark) in PBS (1:30) was added 
to each well. After one hour incubation at room temperature and three washes 
with 1% bovine serum albumin-PBS, 70 μl of secondary antibody (Alexa Fluor 
488, goat anti-rabbit IgG, Molecular Probes, Eugene, OR, USA) in PBS (1:500) 
was added to each well. The plates were incubated for 1 h protected from light, 
then washed four times with PBS and measured for fluorescence with a Victor2 
multilabel counter 1420 (PerkinElmer, Boston, MA, USA) using excitation and 








Supernatant from both chambers
Figure 4 Schematic presentation of cell insert model to study interaction of probiotics, H. pylori and epithelial 
cells. TER, Transepithelial electrical resistance
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Epithelial cell integrity
Bacteria were added in various concentrations to the apical compartments of cell-
culture inserts, and the cultures were incubated at +37°C for 42 h. Transepithelial 
electrical resistance (TER), as an index of epithelial integrity, was measured with 
the EVOM™ Epithelial Voltohmeter using “chopstick” electrodes (World Precision 
Instruments, Stevenage, UK). TER across monolayers was measured at the indicated 
time points during 42 h incubation. Measurements are expressed in Ω/cm2 after 
subtracting the mean resistance of cell-free inserts. Prior to experimentation, the 
Caco-2 monolayers were differentiated for 21 days to acquire a mean baseline TER 
of 950 Ω/cm2. 
Measurement of epithelial cell leakage and apoptosis
Lactate dehydrogenase (LDH) release indicating cell membrane damage and 
caspase-3 indicating apoptosis were measured at 8 and 24 h after H. pylori infection. 
Release of LDH into the culture medium was quantified using a kit from Roche 
Molecular Biochemicals (Mannheim, Germany). Cell culture supernatants were 
collected at 8 or 24 h after H. pylori infection, centrifuged to remove particulate 
matter, and assayed according to the manufacturer’s instructions. Activation of 
caspase-3 was measured with a kit from Molecular Probes. Cells from 12-well 
experiments were lysed and assayed according to the manufacturer’s instructions. 
Fluorescence intensities were measured at excitation and emission wavelenghts of 355 
nm and 460 nm, respectively, after one hour incubation at room temperature. 
Cytokine and eicosanoid measurements
Interleukins IL-8 and IL-10, and PGE2 and LTB4 were analyzed from culture 
supernatants by enzyme-linked immunosorbent assay (ELISA) kits according to 
manufactureŕ s instructions. The assays’ detection limits were 1 pg/ml for the IL-
8 and IL-10 ELISAs (both from CLB, Sanquin, Amsterdam, The Netherlands), 
and 15 pg/ml and 6 pg/ml for the PGE2 and LTB4 assays (both from Cayman 
Chemical, Ann Arbor, MI, USA), respectively. 
4.6 sTaTisTical analysis
In Study I, the results are expressed as means, 95 percent confidence intervals (CI), 
medians or interquartile ranges (IQR). Statistical comparison was made using the 
t test, the Mann-Whitney U test or the Hodges-Lehmann estimation of the shift of 
medians. Median regression analysis (also known as the least absolute value model) 
was used to estimate the difference between adjusted medians with the baseline 
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value as a covariate. Measures with a discrete distribution are expressed as counts 
(%) and analyzed by the chi-square test, Fischer’s exact test or the Fisher-Freeman-
Halton test. Hochberg’s adjustments were performed to correct significance levels 
for the multiple tests.
In Studies II and III, Wilcoxon’s signed rank test for paired samples was used 
for the comparison of alterations among groups. Two-way Student’s t test was used 
in Study II to analyze the microbial results between the placebo and probiotic 
groups. Logarithmic transformation was performed when appropriate. A p value 
<0.05 was considered significant. In Study IV, statistical differences were analyzed 
by one-way analyses of variance (ANOVA) and Bonferroni multiple comparisons 
testing with p values <0.05 considered significant. GraphPad Prism version 3.0 




The main results of Studies I-IV are presented in the following chapters.
1. EffEcTs of probioTics on ThE  
TolErabiliTy and Efficacy of  
H. pylori  EradicaTion TrEaTMEnT
The probiotic combination therapy significantly reduced the total symptom score 
during H. pylori eradication treatment. During the eradication week, the baseline-
adjusted median symptom score decreased in the probiotic group, whereas an 
increase was seen in the placebo group, -3 (95% CI: -7 to 0) vs. 3 (95% CI: -1 to 
6) respectively, p = 0.038 between the two groups. The median total symptom 
score was 22 (IQR 15, 34) in the probiotic group and 32 (IQR 13, 46) in the 
placebo group. As to individual symptoms, major differences in epigastric pain and 
bloating were observed between the groups.
The probiotic combination therapy did not significantly increase the eradication 
rate of the treatment even though the eradication percentages appeared to differ. 
Eradication efficacy was evaluated at four weeks (13C-UBT) and at four months 
(EIA serology) after completion of the course of triple therapy. H. pylori eradication 
was verified by both 13C-UBT and serology in 21 out of 23 subjects [91% (95% CI: 
72 to 99)] in the probiotic therapy group and 19 out of 24 [79% (95% CI: 56 to 
93)] in the placebo group (p = 0.42).
rEsulTs
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No significant differences were observed in defecation frequencies nor in 
diarrhea between the placebo group and the probiotic group. 
To prove the viability and survival of the probiotic bacteria during antibiotic 
treatment and to test patient compliance objectively, concentrations of two 
probiotic bacteria (LGG and PJS) were analyzed from fecal samples. Despite the 
triple treatment for H. pylori eradication, the mean fecal concentration of LGG 
increased in the probiotic therapy group by 2.1 log10 CFU/g (p < 0.001) and 
attained a maximal increase of 2.35 log10 CFU/g (p < 0.001) by the end of the 
intervention compared to the placebo group. The mean fecal concentration of PJS 
showed an even greater increase, of 3.7 log10 CFU/g (p < 0.001) after the first week, 
and a 2.8 log10 CFU/g (p < 0.001) increase at the end of the trial, compared to the 
placebo group.
To sum up, the probiotic combination was able to reduce the subjects’ 
total adverse symptoms during the eradication week. The fecal recovery 
of LGG and PJS showed that these probiotics are able to survive 
gastrointestinal transit during intense antimicrobial treatment for H. pylori 
eradication. 
2. EffEcTs of probioTics on  
MicrobioTa following H. pylori 
EradicaTion TrEaTMEnT
During eradication treatment, the total bacterial counts decreased significantly 
in the fecal samples of both the placebo and the probiotic group. The counts of 
bifidobacteria, lactobacilli/enterococci and clostridia also decreased significantly. 
Furthermore, the fecal species F. prausnitzii and E. rectale – C. coccoides and the 
total anaerobe population were strongly suppressed in both study groups. In 
contrast to the placebo group, where aerobic bacteria significantly decreased after 
antimicrobial treatment, the number of total aerobes clearly increased during the 
treatment and intervention when compared to the baseline in the probiotic group.
The ratio of anaerobes/aerobes was significantly increased in the placebo 
group during the eradication treatment. In the probiotic group, there was no major 
change in the ratio of anaerobes/aerobes during the trial. An increase was found in 
the number and prevalence of fecal yeasts in both groups after H. pylori eradication 
treatment.
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In the post-eradication period, the counts of bifidobacteria and lactobacilli/
enterococci groups were clearly lower at end of the intervention than at the baseline. 
When the bacterial populations in the two groups were compared, the number of 
total aerobes and lactobacilli/enterococci between Weeks 1 to 4 was found to be 
significantly higher in the probiotic group than in the placebo group (Figure 5, A 
and B). After the antimicrobial treatment, a significant decrease was also found in 
the numbers of Enterobacteriaceae in both study groups.
There were no major differences in the microbiota of H. pylori infected patients 
and healthy control volunteers. Only the number of total anaerobes and clostridia 
were slightly, but significantly lower in H. pylori infected patients. 
To summarize, significant reductions in the amount of total bacteria, 
bifidobacteria, lactobacillus/enterococcus group bacteria, bacteroides, 
C. histolyticum group, E. rectale - C. coccoides group, F. prausnitzii, total 
anaerobes and enterobacteria were seen in the fecal samples of both the 
placebo and probiotic group during the anti-H. pylori treatment and in 
the post-treatment period. Probiotic combination slightly stabilized the 
microbial disturbances during H. pylori eradication treatment since the 
number of lactobacilli/enterococci alterations decreased and the total 
amount of aerobes increased.
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Figure 5 Fecal concentrations (CFU/g feces) of total aerobes (A) and lactobacilli/enterobacteria group bacteria 
(B) in the two study groups. Values are expressed as mean (± SEM), n = 19–20/group. * p<0.05 and 














3. EffEcTs of probioTics in unTrEaTEd 
H. pylori  infEcTEd paTiEnTs
Before probiotic ingestion, at the baseline, a detectable level of LGG was found 
in the fecal samples of eight of the 12 subjects. LC705 was detected in five, PJS 
in two and Bb12 in three of the subjects. The amount of all four probiotics in 
feces increased significantly from baseline values during the intervention in all 
patients.
The recovery of individual probiotic strains and lactic acid bacteria in gastric 
and duodenal mucosal biopsies was analyzed from a total of 72 samples. At the 
baseline, LGG was detected in the duodenum of one of the 12 subjects. At the 
end of the intervention, three of the subjects were found to have LGG: two in the 
corpus and one in the duodenum. Other probiotic strains, LC705, PJS and Bb12, 
were not found in any of the biopsy samples before or after the intervention.
Histologically chronic inflammation in the antrum and corpus level remained 
the same in all patients during the intervention. In contrast, inflammation activity 
decreased in two subjects’ antrums and also in one subject’s corpus, but these 
effects did not achieve statistical significance. All H. pylori uninfected patients had 
healthy, non-inflamed gastric and duodenal mucosa.
During the eight week probiotic treatment, the 13C-UBT values appeared to 
decrease between baseline and Week 8 (p=0.063). Mean values for baseline and 
after probiotic treatment were 22.3 (range 13.8–44.5) and 16.3 (range 6.2–34.1), 
respectively.
The effect of the probiotic combination intervention on several non-invasive 
gastric serum markers was determined. Serum gastrin-17 decreased significantly 
from the baseline level in the H. pylori infected group (p=0.046). Other markers 
studied, e.g. pepsinogens I, II and the pepsinogen I/II ratio, remained stable 
throughout the intervention. Marked differences were found between H. pylori 
positive and H. pylori negative subjects in all serum markers evaluated.
To sum up, the individual bacterial strains in the probiotic combination, 
when administered twice daily for 8 weeks, could be recovered in 
all of the subjects’ fecal samples. Of the probiotics used, LGG showed 
marginal ability to adhere to the upper gastrointestinal tract mucosa. 
Furthermore, the probiotic intervention decreased serum gastrin-17 
levels and appeared to lower 13C-UBT values.
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4. characTErisTics of probioTics in  
H. pylori  infEcTEd EpiThElial cElls
A summary of the in vitro results is shown in Table 8.
Adhesion
LGG inhibited H. pylori adhesion by half already at the concentration of 107 
CFU/ml. At this concentration, none of the other probiotics studied inhibited H. 
pylori adherence. LC705, Bb99, and the combination were effective at one order of 
magnitude greater concentrations, whereas PJS inhibited H. pylori adherence only 
with the highest concentration of 109 CFU/ml. Maximal inhibitory effects were 
seen with 109 CFU/ml concentrations of LGG and PJS. 
Barrier function
When H. pylori-infected epithelial cells were pretreated with LGG, LC705, or 
the combination, an increase in transepithelial resistance (TER) (p<0.001) was 
observed during the first 8 h, suggesting barrier function enhancement. After 18 
h of incubation, however, this effect was counteracted with a TER decline and the 
potentiation of H. pylori-induced barrier deterioration. 
H. pylori increased LDH release from epithelial cells when measured at 8 h, 
suggesting induction of acute cell membrane leakage. Pretreatment with LGG, 
LC705, PJS, or the combination counteracted this H. pylori-induced effect. At 8 h 
of incubation, no significant effects on caspase-3 activity were observed, suggesting 
that neither H. pylori nor the probiotic pretreatments promoted acute apoptotic 
effects. After 24 h of incubation, probiotic bacteria and their combination 
potentiated LDH-release from H. pylori-infected Caco-2 cells, suggesting that the 
probiotics induced infected cells to cause membrane damage.
Immunoinflammatory responses
Pretreatment with LGG, LC705, or PJS inhibited IL-8 secretion from H. pylori 
infected cells, but had no effect in uninfected cells. In contrast, Bb99 and the 
combination of probiotics induced a massive increase in IL-8 secretion as compared 
to the control cell monolayer or to the H. pylori infected monolayer. The Bb99 
strain also substantially potentiated IL-8 release from H. pylori infected cells. Of 
all probiotic strains, only the effect of Bb99, although diminished, persisted when 
the probiotics were used as a combination. A weak measurable release of IL-10 
was detected after the cells’ exposure to H. pylori (1.9 pg/ml at concentration 108 
CFU/ml and 2.0 pg/ml at 107 CFU/ml) and also after exposure to Bb99-pretreated 
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H. pylori-infected cell monolayer (2.6 pg/ml at concentration 108 and 3.5 pg/ml 
at concentration 107). This anti-inflammatory effect was lost when the probiotics 
were used as a combination.
H. pylori dose-dependently increased PGE2 and LTB4 release from Caco-2 cells. 
Treatment of H. pylori-uninfected cells with LGG, LC705, and PJS also induced 
the production of PGE2. This effect was not seen with Bb99 or the combination. 
However, pretreatment of H. pylori-infected cells with LC705, PJS, or Bb99 
attenuated H. pylori-induced PGE2 production. An opposite and enhancing effect 
was observed with LGG and the combination treatment. 
A decrease in the release of H. pylori-induced chemotactic proinflammatory 
LTB4 was evident by pretreatment with LC705. In contrast, Bb99 produced a 
1.7-fold increase and the combination pretreatments a 3.5-fold increase in LTB4 
release from cells infected with the lower concentration of H. pylori. The anti-
inflammatory effect of LC705 was lost when the probiotics were combined, and 
the combination persistently increased LTB4 release also from cells infected with 
the higher concentration of H. pylori. Probiotics had no effect on uninfected cells’ 
LTB4 release.
To sum up, all strains and their combination inhibited adherence of 
H. pylori to Caco-2 cells. The acute H. pylori-induced membrane damage 
was alleviated by LGG, LC705, PJS and the combination. This was in 
accordance with the epithelial cell barrier strengthening effect found 
with LGG, LC705 and the combination. Strain-specific pro-inflammatory 
effects were shown to dominate over the anti-inflammatory components 




























































































































































































































































































































































































During H. pylori eradication treatment, many patients experience antibiotic-
associated adverse events, such as bloating, epigastric pain and diarrhea. Even if 
the short duration of the treatment helps to prevent most discontinuations, the 
usual eradication rates in clinical trials remain at approximately 80%. Previous 
studies investigating anti-H. pylori regimens have revealed that the gut microbiota 
is significantly altered during eradication treatment, and specifically the 
concentrations of lactobacilli and bifidobacteria decrease substantially. 
As probiotic bacteria have been shown to have beneficial effects on several 
disorders of the gastrointestinal tract, it was investigated whether a probiotic 
mixture of four strains (L. rhamnosus GG, L. rhamnosus LC705, P. freudenreichii 
JS and B. breve 99 or B. lactis Bb12) would be able to alleviate the adverse effects 
associated with anti-Helicobacter treatment and increase the efficacy of the 
eradication treatment. Furthermore, the mechanisms of action by which probiotics 
provide protection from H. pylori infection or promote therapy still remain more or 
less obscure. Thus, the effects of probiotics on upper gastrointestinal tract mucosa 
were assessed in H. pylori infected and uninfected patients, and the cross-talk 
between intestinal epithelial cells, probiotic bacteria and H. pylori was investigated 




Selection of the probiotic strains
The justification for the use of the chosen probiotic strains and combination may 
be questioned. However, two earlier studies by Armuzzi et al. (2001a, 2001b) have 
found that LGG is effective in decreasing the adverse effects related to H. pylori 
eradication treatment, but does not increase the H. pylori eradication rate. Also, it 
was shown that L. rhamnosus GG is able to antagonize H. pylori induced TNF-α 
production by murine macrophages in vitro (Peña et al. 2003). L. rhamnosus LC705 
(LC705) and Propioniobacterium freudenreichii ssp. shermanii JS (PJS) have been 
shown to antagonize yeasts in the manufacture of sour milk products (Suomalainen 
and Mäyrä-Mäkinen 1999). Furthermore, the combination of LGG, LC705 and 
PJS has reduced the prevalence of oral Candida infection in the elderly (Hatakka 
et al. 2007). B. lactis Bb12 combined with L. acidophilus La5 have turned out to 
be beneficial in H. pylori infection with and without anti-helicobacter treatment 
(Cremonini et al. 2002, Wang et al. 2004, Sheu et al. 2006). Furthermore, the 
combination of probiotics have been observed to be effective in the treatment 
of irritable bowel syndrome (IBS) in two double-blind, randomized, placebo-
controlled long-term clinical studies (Kajander et al. 2005, Kajander et al. 2006). 
Moreover, it has been demonstrated that this probiotic combination and LGG have 
opposite immunological effects in infants with atopic eczema-dermatitis syndrome 
(Pohjavuori et al. 2004, Viljanen et al. 2005a, 2005b). 
Assessment of H. pylori infection status
There is no single standard for the assessment of H. pylori infection status. 
Therefore, the presence of H. pylori infection was evaluated by several methods in 
the present study. In Study I, the invasive methods were not possible since volunteers 
did not have indications for gastroscopy, and thus non-invasive urea breath test 
(UBT) served as the standard. The limitation of this UBT method is that the 
gastric microbiota of some subjects may also produce urease without any H. pylori 
infection. To increase the reliability of the diagnoses, all positive screening results 
were confirmed also with an in-house EIA-based serological method that is well-
validated locally (Rautelin and Kosunen 2004). The same subjects’ blood samples 
before and after therapy were run in parallel. In the third study, H. pylori infection 
was identified by both invasive methods (histology and rapid biopsy tests) and 
non-invasive ones (UBT and serology).
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Evaluation of adverse events
A standardized and validated questionnaire, modified from de Boer et al. (1996), 
was used to evaluate adverse effects in Study I. In this questionnaire, 10 treatment-
related symptoms were systematically recorded daily for one week before the 
eradication treatment (baseline), during the treatment (eradication week) and also 
for three weeks thereafter (follow-up intervention). Correct diary completion was 
checked at the study meetings after baseline, during the intervention and at the 
end of the intervention. Diarrhea was evaluated using the criteria recommended 
by the World Health Organization. In order to gain a solid understanding of 
“background” symptoms, an evaluation period for baseline symptoms prior to the 
study was considered important because participants commonly have, for example, 
questionnaire-induced greater subjective awareness of symptoms. Most of the 
previous studies have not considered the symptoms before treatment, and thus all 
of the symptoms recorded during or after treatment were regarded as adverse events 
in those studies (Canduzzi et al. 2000, Armuzzi et al. 2001a, 2001b, Sheu et al. 
2002, Cremonini et al. 2002, Tursi et al. 2004, Sykora et al. 2005). However, part 
of these baseline symptoms could be related to an ongoing H. pylori infection or 
undiagnosed dyspepsia. In any case, this fact does not significantly interfere with 
the conclusions drawn from our study since there were no significant differences in 
baseline symptom scores between the two study groups and all analyses were made 
with baseline as a covariate. We also used median values instead of means to better 
accommodate for the small sample size and rather skewed data. 
Microbiological analysis
There are several methodological difficulties in investigating intestinal microbiota 
alterations. The traditional fecal culture method has been regarded as the standard 
for studying bacteria. However, microbes may fail to grow on artificial agar, the 
selectivity of culture media used may be poor, microbes may even prevent the 
growth of others, or some species may be misidentified (for review, see Tannock 
2001). To obtain a more accurate microbial profile, we have used novel molecular 
techniques based on FISH and quantitive PCR, which provide rapid quantitative 
and qualitative information on the composition of the intestinal microbiota, 
in addition to the traditional culture methods (for review, see Zoetendal et al. 
2006). 
Survival of probiotics
To investigate survival of the probiotic bacteria during antibiotic treatment and 
probiotic intervention, and to test patient compliance objectively, concentrations of 
two probiotic bacteria (LGG and PJS) were analyzed from fecal samples in Study 
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I and all four individual strains in Study III. The amount of probiotic bacterial 
strains recovery from feces increased markedly following the probiotic intervention 
in both Studies I and III, indicating excellent survival of gastrointestinal transit 
and excellent patient compliance during the studies. 
LGG was the only probiotic strain recovered from biopsies, which is consistent 
with several in vitro studies indicating that LGG is a very well adhering strain 
(Tuomola and Salminen 1998, Tuomola et al. 2000). Host genetic factors and the 
original bacterial community adapted to this upper gastrointestinal niche (Bik et 
al. 2006) probably explain why only a minority of the patients had detectable levels 
of LGG in the biopsies. 
Epithelial cell model
The relevance of the choice of a single intestinal cell line, Caco-2, for studying the 
effects of probiotics in H. pylori infection may be questioned, and this selection 
may to some extent limit the drawing of conclusions. However, none of the gastric 
epithelial cell lines available to date (e.g. AGS, MKN-28) are able to grow as a 
tightly sealed polarized monolayer. Therefore, the Caco-2 cell line which displays a 
well organized brush border with good transepithelial resistance and a capacity to 
release several inflammatory mediators upon treatment with H. pylori (Hidalgo et 
al. 1989, Kim et al. 2002) was chosen. Also, it provides a suitable and highly cited 
method for studying the effects of infectious agents as well as probiotic bacteria (for 
reviews, see Servin and Coconnier 2003). Moreover, a single well-characterized 
experimental gut epithelial cell model was chosen to enable unequivocal head-to-
head comparison of probiotics’ effects on the level of cell responses to infection 
with a live pathogen, H. pylori. Comparison of responses by different cell models 
was not the aim of this study. 
2. Main rEsulTs 
2.1 EffEcTs of probioTics on  
ThE EradicaTion TrEaTMEnT of H. pylori
Generally 20–30% of first-line anti-H. pylori treatments fail (Fischbach et al. 
2002), and one of the important causes for the failure in clinical practice is the 
high prevalence of adverse effects (Deltenre et al. 1998). In the present study, the 
probiotic combination was effective in alleviating the adverse effects of H. pylori 
eradication treatment. The tolerability of the treatment was assessed primarily 
by total symptom score, which takes into account both the frequency and the 
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severity of the symptoms with baseline symptoms as a covariate. The hypothesized 
mechanisms of probiotics in the attenuation of symptoms are largely unknown. 
It can be speculated that probiotic supplementation may resist alterations of 
microbiota or diminish the antibiotic-induced overgrowth of potentially harmful 
microorganisms. In support of this hypothesis, probiotic combination stabilized 
disturbances in Lactobacillus and Enterococcus group bacteria and the total aerobes 
following H. pylori eradication treatment. Furthermore, probiotics, specifically 
LGG and PJS, were able to survive in the gastrointestinal tract during eradication 
treatment. It may be that these particular species are, to some extent, resistant to 
antimicrobial therapy, because concentrations of lactobacilli and bifidobacteria in 
general have been shown to decrease during the eradication of H. pylori (Bühling 
et al. 2001, Madden et al. 2005, Plummer et al. 2005) Thus, the stabilization of 
the microbiota by probiotic therapy could explain, at least in part, the alleviation 
of symptoms in the present study. 
The eradication rate, exceeding 90% in the probiotics group, is considered 
high. However, the small sample size of Study I does not allow one to draw firm 
conclusions, although our results are in line with previous studies with other 
probiotics (for reviews, see Hamilton-Miller 2003, Gotteland et al. 2005). It is of 
interest that while the H. pylori infection of two volunteers receiving probiotics 
in this study was not successfully eradicated, their 13C-UBT value decreased to 
borderline levels. In the placebo group, none of the five treatment failures had 
borderline results from 13C-UBT. 13C-UBT values have been reported to correlate 
positively with H. pylori colonization (Perri et al. 1998, Zagari et al. 2005). This 
suggests that probiotic therapy could have a colonization-lowering effect on 
H. pylori infection during eradication treatment as measured by 13C-UBT. This 
finding is also supported by the results from Study III, since probiotic intervention 
appeared to decrease bacterial load when administered to untreated patients.
Although the numbers of bifidobacteria, lactobacilli and enterococci, bacteroides 
and F. prausnitzii increased after the cessation of the triple therapy, they did not 
reach baseline levels even after the 9-week follow-up period. These quite long-term 
disturbances are partly in accordance with earlier studies of anti-H. pylori treatment 
with clarithromycin and metronidazole, showing that the amounts of lactobacilli 
and bifidobacteria increase but do not reach the baseline level 4 weeks after the 
treatment (Bühling et al. 2001). It can be speculated that long-term changes in the 
microbiota could contribute to the long-term persistence of resistant enterococcal 
populations after anti-Helicobacter treatment as demonstrated by others; these 
resistant bacteria groups could serve as reservoirs of resistance genes (Sjölund et 
al. 2003). 
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2.2 EffEcTs and characTErisTic of  
probioTics in H. pylori infEcTion
Probiotic intervention decreased gastrin-17 levels in H. pylori infected patients. 
H. pylori infection is associated with increased basal and stimulated plasma 
gastrin concentrations and acid output, especially in patients with duodenal ulcers 
(Schubert 1999). Elevations in gastrin-17 levels have also been associated with an 
increased risk for gastric atrophy and cancer (Fox and Wang 2002). The exact 
mechanisms mediating the effects are not known, but it is suggested that both 
bacteria products and the inflammatory infiltrate are able to stimulate gastrin and 
acid secretion (Schubert 1999). Our study is the first, as far as we know, to show that 
probiotics decrease serum gastrin-17. Furthermore, probiotic intervention appeared 
to reduce 13C-UBT values. The density of H. pylori in mucosa is strongly related 
to the gastric inflammation and secretion capacity (Di Mario et al. 2006), and the 
13C-UBT is an indirect indicator of H. pylori density in gastric mucosa (Perri et al. 
1998, Zagari et al. 2005). A moderate reduction in values (approximately 27%), as 
shown in the present study, suggests that the total amount of Helicobacter in the 
stomach decreases during the intervention. Support for this conclusion is found in 
some recent studies in which certain probiotic strains or combinations were seen 
to reduce H. pylori density (Michetti et al. 1999, Sakamoto et al. 2001, Cruchet 
et al. 2003, Wang et al. 2004, Sykora et al. 2005). Our results are also consistent 
with these findings, indicating that probiotics are not able to eradicate H. pylori 
infection. 
The mechanisms behind the decreased gastrin-17 seem to be unrelated to the 
adherence of probiotics in the gastric mucosa. Several probiotic strains have been 
shown to decrease IL-8 and TNF-α (Morita et al. 2002, Peña et al. 2003, Zhang 
et al. 2005), and this could hypothetically be one mechanism in which probiotics 
interfere with gastrin-17 release, since during H. pylori-induced inflammation 
these mediators have been implicated in increasing gastrin production from G 
cells (for review, see Walter 2006). However, based on the present study, a more 
logical explanation for the reduced gastrin-17 after probiotic consumption could 
be the decreased Helicobacter amount in the stomach as indicated by 13C-UBT 
measurements, and this could possibly lead to decreased release of pro-inflammatory 
cytokines in the stomach. 
After probiotic intervention, L. rhamnosus GG adhered to a minority of 
patients’ upper gastrointestinal mucosas, but all probiotics survived well through 
the gastrointestinal tract transit. This is supported by the in vitro study (IV) since 
probiotics affected barrier function and immunoinflammatory mediators upon 
H. pylori infection by mechanisms unrelated to their ability to inhibit pathogen 
adhesion. Recent results indicate that beneficial effects of probiotics could be, at 
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least partially, mediated by their own DNA rather than their ability to colonize 
the gut (for review, see Mottet and Michetti 2005). On the other hand, adhesion 
of probiotics at the target sites would possibly result in an enhanced exposure to 
probiotics at the place of action, perhaps achieving the desired responses, such as 
immune modulation at a lower dosage.
Probiotics exerted strain-dependent biphasic effects on the barrier function of 
H. pylori infected Caco-2 cells. In the present study, the monolayer’s resistance, 
TER, as an indicator of epithelial barrier function, was acutely tightened by the 
two Lactobacillus rhamnosus strains (LGG and LC705), whereas after longer 
exposure, these treatments potentiated the decline in barrier function in H. pylori 
infected epithelial cells. In conjunction with measuring transepithelial resistance, 
we also evaluated the morphological integrity of all cell layers, apoptosis and cell 
leakage. No cell detachment indicating necrosis was observed. In accordance with 
TER results, we found that both of the Lactobacillus strains studied, LGG and 
LC705, inhibited significantly caspase-3 when cells were infected with H. pylori. 
Similar acute enhancement has been reported for the probiotic mixture VSL#3 
(Otte et al. 2004), and a decreased integrity of the epithelial cell monolayer under 
inflammatory conditions has been reported for probiotics (Menard et al. 2004). 
Our results show a time-dependent dual effect of probiotics on intestinal barrier 
function and thus present a novel rationale to explain the varying outcomes of 
previous reports. 
For evaluation of the effects of probiotics on the different immunoinflammatory 
responses, we measured the release of IL-8, IL-10, PGE2, and LTB4 from the 
epithelial cells in vitro. Both the Lactobacillus strains (LGG and LC705) and the 
propionibacteria PJS were able to reduce H. pylori-induced IL-8 production. These 
results are in accordance with reports on non-pathogenic bacteria suppressing IL-8 
production in colon epithelial cells stimulated with TNF-α (Hidalgo et al. 1989, 
Kim et al. 2002, Otte et al. 2004). 
H. pylori dose-dependently increased PGE2 and LTB4 release from epithelial 
cells. The present findings support the role of intestinal PGE2 and LTB4 in 
mediating mucosal inflammation in H. pylori infection. LC705, PJS, and Bb99 
were able to suppress the PGE2 release induced by H. pylori, despite the fact that 
LC705 and PJS alone activated PGE2 production. Pretreatment with LC705 
evidently reduced the H. pylori-induced release of chemotactic pro-inflammatory 
LTB4. In contrast, LTB4 release from cells infected with the lower concentration 
of H. pylori was increased 1.7-fold with Bb99 and 3.5-fold with the combination 
pretreatments. Probiotics had no effect on uninfected cells’ LTB4 release. 
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Taken together, the present results suggest some degree of beneficial 
effect of this probiotic combination on H. pylori infected subjects, at 
least in terms of decreasing gastrin-17 levels. Moreover, these results 
show that probiotics exert their effects via mechanisms unrelated 
to their adherence to the gastric mucosa. The combination does not 
necessarily provide additional immunomodulatory benefit due to the 
varying and counterbalancing effects of the individual components. 
However, the immune-stimulatory effects of the probiotic combination 
may have beneficial indirect effects on H. pylori infected patients, since 
the persistence of the H. pylori infection suggests that the host immune 
response is not effective in eliminating the infection.
69
The present study investigated the effects of a probiotic combination supplementing 
recommended H. pylori eradication treatment and probiotic intervention in H. 
pylori infected and uninfected patients. Furthermore, the effects of individual 
probiotics and the combination were characterized using an in vitro model of H. 
pylori infection.
In conclusion, the probiotic combination alleviated the adverse events associated 
with anti-H. pylori therapy following eradication treatment and stabilized the 
microbiota. The multispecies probiotic combination evidently had some degree 
of beneficial effect on H. pylori infected subjects, at least in terms of decreasing 
gastrin-17 levels, possibly by decreasing the H. pylori load in the stomach, as 
indicated by 13C-UBT measurements. The results suggest that the regular intake 
of probiotics does not eradicate H. pylori, but could be considered as an adjuvant 
to the conventional antibiotic therapy of H. pylori infection. Probiotics exert their 
effects via mechanisms unrelated to their adherence to the gastric mucosa, and 
thus the interference exerted by this probiotic combination on H. pylori could be 
due to the probiotics' indirect immunomodulating properties.
In order to further evaluate the value of this probiotic combination in H. pylori 
infection, studies comprising larger numbers of patients are necessary. Cutting-
edge approaches, such as DNA microarray, would also be of interest to define the 
effects of anti-Helicobacter pylori treatment and probiotics on gut microbiota and 
to create molecular maps of host-pathogen interactions. The goal of the research 
should be to provide H. pylori infection eradication treatment with optimal efficacy 
and tolerability to avoid excess use of antimicrobials and to offer alternative ways of 
controlling H. pylori infection if eradication treatment is not recommended. 
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